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ABSTRACT 
            Macroautophagy (hereafter autophagy) is a fundamental cellular process that removes 
unnecessary or dysfunctional components. It allows the orderly degradation and recycling of 
cellular components. Mitophagy refers to the selective removal of damaged mitochondria via 
autophagy pathway. In addition to utilizing core autophagic machinery components, mitophagy 
exploits a variety of molecules, such as PTEN-induced putative kinase protein 1 (PINK1) and 
Parkin, to identify and eliminate damaged or superfluous mitochondria. Dysregulation of 
autophagy and mitophagy contributes to a variety of human disorders, including cardiovascular 
diseases, such as atherosclerosis and diabetic cardiomyopathy. Vascular smooth muscle cells 
(VSMCs) are a major component of the vascular media, and are vital for maintaining vessel 
homeostasis. Migration of VSMCs from the media to intima occurs during the development of 
atherosclerosis. Although alterations in autophagy activity have been reported in atherosclerosis, 
further investigation is required to delineate the mechanism by which autophagy regulates 
microtubule stability and cell migration. Diabetic cardiomyopathy, which develops in the 
absence of traditional risk factors, is a major cause of heart failure in Type 2 diabetic patients. 
Although multiple factors may collectively contribute to the development of diabetic 
cardiomyopathy, there is an urgent need to determine the role of autophagy in the development 
of diabetic cardiomyopathy.  
            This dissertation has explored the role of autophagy and mitophagy in regulating VSMCs 
migration as well as in the development of diabetic cardiomyopathy, using comprehensive 
physiological, pathophysiological, molecular, and genetic approaches. We show that activation 
of autophagy selectively degrades KAT2A/GCN5, a histone acetyltransferase that acetylates α-
tubulin in VSMCs, leading to microtubule instability and promotion of VSMC migration. In 
diabetic heart, defective autophagy and PINK1/Parkin-mediated mitophagy are regulated by 
bromodomain-containing protein 4 (BRD4), a bromodomain and extra-terminal domain (BET) 
family of proteins. Administration of JQ1, one of the BET bromodomain inhibitors, restores 
PINK1/Parkin-mediated mitophagy and prevents high-fat-diet induced diabetic cardiomyopathy. 
Collectively, our work suggests that autophagy suppression in VSMCs is an important 
therapeutic target for atherosclerosis and that suppression of BRD4 may be a new therapeutic 
approach for diabetic cardiomyopathy. 
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1 INTRODUCTION  
1.1 Overview of autophagy 
1.1.1 Molecular machinery of autophagy 
            Autophagy is an intracellular catabolic pathway in which long-lived proteins and 
organelles are delivered to lysosomes for degradation. There are three types of autophagy: 
macroautophagy, microautophagy, and chaperone-mediated autophagy. The term “autophagy” 
usually indicates macroautophagy (1). Autophagy consists of several sequential steps, including 
sequestration, transport to lysosomes, degradation, and utilization of degradation products. 
            Autophagy process is controlled by autophagy-related genes (Atgs). In mammalian cells, 
autophagy induction is controlled by the serine/threonine protein kinase ULK1 (unc-51-like 
kinase 1, a homologue of yeast Atg1) complex. Other subunits include Atg13, FIP200 (focal 
adhesion kinase family interacting protein of 200 kD) and Atg101 (2-4). Basal-level autophagy is 
very low under normal conditions. As the main nutrient-sensitive pathway, starvation stress 
generally activates AMP-activated protein kinase (AMPK) and inactivate MTORC1 (mTOR 
complex 1) pathways. AMPK and MTORC1 signals regulate complex of ULK1 and ATG13 
activity by phosphorylation or dephosphorylation of ULK1 (5,6). The activated ULK1 complex 
translocates to the phagophore assembly site (PAS) and regulates the class III 
phosphatidylinositol 3-kinase (PtdIns3K) complex (7). The PtdIns3K complex consists of VPS34 
(vacuolar protein sorting 34), as well as VPS15, Atg14L (Atg14-like), and Beclin-1. This 
complex is responsible for the production of the phospholipid phosphatidylinositol 3-phosphate 
(PI3P) at PAS. Activation of the PtdIns3K complex causes induction of autophagy, which 
involves formation of an isolation membrane to which the Atg proteins are recruited. The 
expansion of the isolation membrane is regulated by two ubiquitin-like protein conjugation 
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pathways, Atg12-Atg5 and the microtubule-associated protein light chain 3-
phosphatidylethanolamine (LC3-PE). The E1 enzyme Atg7 and the E2 enzyme Atg10 
sequentially conjugates Atg12 to the lysine residue in Atg5. Atg12-Atg5 then binds to Atg16 to 
form a complex essential for recruitment of LC3 and elongation of the membrane. On the other 
hand, Atg8 (LC3) is first converted to LC3-I by the cysteine protease Atg4. Atg8 is then 
activated by Atg7 (shared with Atg12) and finally conjugated to the amino group of the lipid PE 
via the E2 enzyme Atg3. LC3-PE translocates to the autophagosome membrane in an Atg12–
Atg5–Atg16 complex-dependent manner. Atg8 (LC3) is widely used as a marker to monitor 
autophagy induction (8). When autophagosome formation is completed, it fuses with lysosomes 
to form autolysosomes where the inner membrane of the autophagosome and its contents are 
digested by lysosomal hydrolases (9) (Fig. 1.1).  
1.1.2 Mitophagy as a selective form of autophagy  
Although autophagy has been considered a nonspecific process that randomly sequesters 
cytoplasmic components and delivers to lysosome for degradation and recycling during nutrition 
deprivation, increasing evidence suggests that autophagy can also specifically recognize and 
target redundant or damaged organelles for elimination. For example, specifically degradation of 
peroxisomes (pexophagy) (10), mitochondria (mitophagy), endoplasmic reticulum 
(reticulophagy) (11), and ribosomes (ribophagy) (12).  
            The selective removal of damaged mitochondria via autophagy is referred to as 
mitophagy. Although mitochondria can be engulfed non-selectively together with other cytosolic 
component during general autophagy through the core machinery of autophagy, mitophagy 
exploits a variety of molecules to identify and eliminate damaged or superfluous mitochondria. 
In mammalian cells, mitophagy is defined as two basic types, PINK1/Parkin pathway-mediated 
3 
mitophagy and receptor-mediated mitophagy, according to how mitochondria is delivered to 
autophagosomes (Fig. 1.2). 
1.1.2.1 PINK1/Parkin-mediated mitophagy 
            PINK1 (PTEN-induced putative kinase protein 1) is a serine/threonine kinase that locates 
in part on outer mitochondria membrane (OMM). In healthy mitochondria, PINK1 is imported to 
inner mitochondria membrane (IMM) and rapidly degraded by mitochondrial proteases. Upon 
loss of mitochondrial membrane potential, PINK1 accumulates on the surface of the 
mitochondria (13). Parkin locates in the cytosol and acts as an ubiquitin E3 ligase (14). The 
genes encoding PINK1 (15) and Parkin (16) were firstly found to be mutated in certain forms of 
autosomal recessive Parkinson’s disease and related to mitochondrial quality control. To date, 
the most well-studied mitophagy pathway is the PINK1/Parkin-mediated, which activates 
mitophagy in an ubiquitination-dependent manner.              
            Mitochondrial damage causes PINK1 to accumulate on the mitochondrial surface and 
phosphorylate OMM proteins including MFN2 (mitofusin 2) (17). To maintain mitochondrial 
homeostasis, some E3 ligases, such as Mul1 (18) and March5 (19), constitutively ubiquitinate 
some OMM proteins. PINK1 can phosphorylate these preexisting ubiquitin molecules on 
mitochondria and then activate and recruit Parkin to further ubiquitinate OMM proteins (20). 
Ubiquitinated proteins then recruit LC3 through ubiquitin-binding adaptor, SQSTM1/p62 
(sequestosome 1). The SQSTM1/p62 protein binds to ubiquitinated OMM proteins through its 
ubiquitin-associated domain and to LC3 on the phagophore through its LC3-interacting region 
(LIR) (21). Thus, the binding of SQSTM1/p62 to ubiquitinated mitochondrial proteins provides a 
molecular tether between cargo (mitochondria) and autophagosome (22). 
 
4 
1.1.2.2 Receptor-mediated mitophagy 
          Another type of mitophagy is receptor-mediated mitophagy that relies on various OMM 
proteins such as BNIP3 (BCL2 and adenovirus E1B 19-kDa-interacting protein 3), BNIP3-like 
(BNIP3L)/NIX, and FUN14 domain-containing protein 1 (FUNDC1) (23). These proteins 
contain LIR motifs that bind to LC3 on autophagosome membrane independent of ubiquitin and 
adaptor protein p62 (24). BNIP3L/NIX mediates removal of mitochondria through mitophagy 
during reticulocyte maturation (25,26), and in hypoxia-stimulated mammalian fibroblasts (27). 
Similarly, BNIP3 induces selective removal of the mitochondria in cardiac myocytes (28). In 
addition, BNIP3 and BNIP3L/NIX can directly activate autophagy by disrupting the interaction 
between Bcl2 and Beclin1 (29).  
          FUNDC1 is a conserved outer mitochondrial membrane protein that interacts with LC3 
through LIR at its cytosol-exposed N-terminus. Similar to BNIP3 and BNIP3L/NIX, it is another 
mitophagic receptor that mediates mitophagy. FUNDC1 is maintained in an inactive state 
through phosphorylation on Tyr18 and Ser13 residues by SRC kinase and CK2 respectively. 
Inactivation of SRC kinase during hypoxia decreases phosphorylation of FUNDC1, which 
triggers mitophagy in HeLa cells (30). FUNDC1 can also be regulated by ULK1. Under hypoxia 
condition, ULK1 translocates to mitochondria and phosphorylates FUNDC1 at Ser17, which 
enhances FUNDC1 binding to LC3 in MEFs (mouse embryonic fibroblast) (31). 
          Bcl2-L-13 (Bcl-2-like protein 13) is an OMM protein that induces mitochondrial 
fragmentation and mitophagy in HEK293 cell. The BH domains of Bcl2-L-13 are important for 
the fragmentation of mitochondria, while the LIR facilitates its binding to LC3 and triggers 
mitophagy (32). Importantly, Bcl2-L-13 forms a complex with ULK1 and LC3B which is 
required for Bcl2-L-13-mediated mitophagy (33). 
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1.1.3 Regulation of autophagy 
            Autophagy is an essential process for protein degradation and organelle turnover, which 
is required for maintaining cellular homeostasis and survival (9). Disruption of this process 
results in abnormal cell growth or cell death, and leads to various diseases (34). Thus, the cell 
finely regulates autophagy by multiple molecules/pathways.  
1.1.3.1  Regulation of autophagy by signaling pathways 
   1.1.3.1.1   Amino acid dependent regulation 
          It was known that excess amino acids repress autophagy, whereas amino acid starvation 
stimulates autophagy (35,36). Mammalian target of rapamycin (mTOR) is the primary sensor of 
amino acids and plays a role in the regulation of autophagy. mTOR is the catalytic subunit of two 
distinct protein complexes, known as mTOR Complex 1 (MTORC1) and 2 (MTORC2) with 
distinct composition and function. Amino acids can activate mTORC1 via Ras-related GTPases 
and the guanine-exchange factors. Since nutrient availability and cellular stress modulate 
MTORC1 activity, MTORC1 is a consistent inhibitor of autophagy. Thus inhibition of MTORC1 
by rapamycin or Torin1 inactivates autophagy.  
  1.1.3.1.2   Insulin/growth factor dependent regulation 
          Insulin and insulin-like growth factors inhibit autophagy through activating MTORC1. 
Upon insulin binding, tyrosine residues of the insulin receptor will be auto-phosphorylated, 
which in turn recruit and phosphorylate IRS1 and IRS2 (insulin receptor substrate 1 and 2). As a 
consequence, class I PtdIns3K is recruited to IRS, which then recruits PDK1 (phosphoinositide-
dependent protein kinase 1), leading to phosphorylation and activation of its downstream target 
PKB/Akt (protein kinase B). The activity of MTORC1 is inhibited by the heterodimer 
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TSC1/TSC2 (TSC, tuberous sclerosis complex). PKB/Akt phosphorylates TSC2 and inactivates 
TSC1/TSC2 complex, resulting in activation of MTORC1 (37-39). 
            1.1.3.1.3   Energy/glucose dependent regulation 
          Regulation of autophagy by the cellular energy level or glucose metabolism is also 
important. Although MTORC1 is activated in the presence of amino acids or insulin, it can be 
inhibited by the activation of AMPK when energy falls short (a decreasing ATP/AMP ratio). 
AMPK activation leads to phosphorylation and activation of the TSC1/TSC2 complex, which 
inhibits MTORC1 activity (40). In addition to its ability to inhibit MTORC1, AMPK also 
activates autophagy by direct phosphorylation of ULK1 (41).  
          The Ras/PKA (protein kinase A) signaling pathway plays an important role in glucose 
sensing. In the presence of glucose, PKA is activated by binding with cAMP (cyclic adenosine 
monophosphate). Constitutive activation of the Ras/PKA pathway suppresses autophagy induced 
by TOR inhibition (42). PKA suppressed autophagy through phosphorylation of Atg1 and Atg13, 
which prevents the localization of Atg13 to the PAS (43).  
1.1.3.2 Transcriptional regulation of autophagy 
 1.1.3.2.1   FOXO family proteins 
          The regulation of autophagy involves not only the different signaling pathways, but also a 
coordinated transcriptional activation/suppression of the Atgs or related genes. The FOXO 
(forkhead box-containing protein O) subfamily transcription factors are the first identified 
transcriptional regulators related to the regulation of autophagy in the Drosophila larval fat body 
(44).  Mammalian cells have four FOXO members, FOXO1, FOXO3, FOXO4, and FOXO6. The 
transcription-dependent mechanism regulating autophagy via FOXO3 was discovered in the 
studies of muscle atrophy (45,46). FOXOs are downstream targets of PKB/Akt. Phosphorylation 
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of FOXOs by PKB/Akt inhibits its translocation from cytoplasm to the nucleus, where FOXO3 
directly binds to the promoters of autophagy-related genes such as LC3B, Gabarapl1, atg12, 
Bnip3l, and Bnip3 to activate gene transcription. 
 1.1.3.2.2   TFEB 
          TFEB (transcription factor EB), a master regulator of the autophagy–lysosomal pathway 
(ALP), was discovered and characterized in 2009 (47). Under baseline conditions, TFEB is 
phosphorylated by MTORC1 and binds to the 14-3-3 family of proteins, which leads to its 
retention in the cytoplasm (48). However, MTORC1 inhibition under conditions of nutrient 
depletion (starvation) or rapamycin treatment results in dephosphorylation and nuclear 
translocation of TFEB (49,50), where it binds directly to the promoters of multiple autophagy-
related genes, including ATG4, ATG9B, MAP1LC3B, SQSTM1, UVRAG (UV radiation resistance 
associated protein), and WIPI (WD-repeat domain phosphoinositide interacting protein), 
promoting the genes transcription. TFEB is also a master regulator of lysosomal biogenesis, 
since its overexpression can increase Lamp1 gene expression in mouse liver (49).   
 1.1.3.2.3   ZKSCAN3 and BRD4 
          ZKSCAN3 (ZNF306) belongs to a family of zinc finger transcription factors with KRAB 
and SCAN domains. Unlike TFEB that positively regulates ALP genes expression, ZKSCAN3 
functions as a transcription suppressor and serves as the counterpart of TFEB by transcriptionally 
upregulating the expression of genes related to autophagy and lysosome biogenesis. Silencing 
ZKSCAN3 by shRNA is sufficient to induce autophagy, whereas its overexpression can inhibit 
autophagy in bladder cancer cells. Conversely, starvation-induced autophagy, but not hypoxia- 
and ER stress-induced autophagy, can change its ZKSCAN3 mRNA level and promotes 
cytoplasmic localization, (51). 
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            BRD4 (bromodomain containing 4) is a member of the bromodomain and extraterminal 
(BET) family. It is another transcriptional repressor of autophagy and lysosome genes expression 
via binding to the histone lysine methyltransferase EHMT2/G9a at the gene promoter region. 
Knocking down of BRD4 induces autophagy in vitro and in vivo in response to starvation- and 
rapamycin-induced autophagy. Under starvation conditions, AMPK and SIRT1 (sirtuin 1) can 
displace BRD4 from the promoters of Atgs and genes involved in lysosome function, thereby 
activating autophagy and maintaining cell survival (52). 
1.2 Autophagy and mitophagy in cardiovascular diseases 
1.2.1 Autophagy and mitophagy in different vascular cell types        
           Autophagy can be activated in vascular endothelial cells (ECs) in response to many 
pathophysiological stimuli, such as oxidized low-density lipoprotein (oxLDL) (53), 
lipopolysaccharides (LPS) (54), ROS (55), hypoxia (56), advanced glycation end-products 
(AGEs) (57), and C6-ceramide (58). PINK1/Parkin-mediated mitophagy can be activated by 
palmitic acid (PA) to protect mitochondrial integrity and EC function (59). Although the 
understanding of autophagy and mitophagy in ECs is mainly based on in vitro experiments using 
either human umbilical vein ECs (HUVECs) or bovine aortic ECs (BAECs), increasing evidence 
reveals that autophagy and mitophagy is an essential in vivo process mediating EC function. Atg7 
EC-specific knockout mice exhibit impaired synthesis and release of von Willebrand factor 
(vWF), while retaining normal vessel structure and capillary density (60). Recent studies indicate 
that autophagy or autophagy-dependent mitochondria clearance in ECs can regulate 
angiogenesis. By using EC-specific TFEB transgenic and knockout mice, Fan et al. demonstrate 
that TFEB positively regulates angiogenesis through activating AMPKα and autophagy (61). 
EC-specific Atg5 deletion decreases pathological angiogenesis in a murine model of retinopathy 
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of prematurity by impairing mitochondrial respiratory activity, mitochondrial ROS production, 
and VEGFR2 (vascular endothelial growth factor receptor 2) phosphorylation (62). Autophagy 
increases shear stress-induced eNOS (endothelial nitric oxide synthase) expression. Suppression 
of autophagy leads to defective purinergic signaling to eNOS phosphorylation and NO 
production via PKCδ (63,64). EC-specific ATG7 knockout mice attenuates thrombosis by down 
regulating the expression of tissue factors (TF), which are procoagulant molecules (65). Taken 
together, these findings indicate that the proper regulation of autophagy and mitophagy is critical 
in maintaining ECs survival and endothelial function such as angiogenesis, NO production, and 
thrombosis.  
            Vascular smooth muscle cells (VSMCs) are the major component of the vascular system. 
Autophagy can regulate VSMCs viability, proliferation, and phenotype switch. Similarly to the 
ECs autophagy, VSMCs autophagy can be stimulated by many vascular disease-related stimuli 
and serve as a prosurvival mechanism. For example, excessive free cholesterol in VSMCs 
activates autophagy and promotes cell survival by degradation of dysfunctional organelles such 
as mitochondria and endoplasmic reticulum (66). Autophagy can also be stimulated by oxidized 
lipids. Modest amounts of ox-LDL enhances autophagy and apoptosis, however, higher 
concentrations of ox-LDL induces high levels of apoptosis but suppresses autophagy (67). 
Moreover, PINK1/Parkin-mediated mitophagy can be activated in VSMCs to prevent oxLDL- 
induced cell death (68). Other pathophysiological stimuli, such as AGEs (69), hypoxia (70), and 
inflammatory cytokines (71) also stimulate autophagy in VSMCs. Autophagy is important in 
maintaining VSMCs viability, as VSMCs-specific Atg7 knockout mice are more resistant to 
oxidative stress-induced cell death (72). Unlike many other mature cell types in the adult body, 
VSMCs do not terminally differentiate but retain a remarkable plasticity. Upon stimulation with 
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various stimuli, it can shift between a differentiated, contractile phenotype and a dedifferentiated, 
synthetic phenotype (73). Autophagy may play a role in this phenotype switching. Treatment of 
VSMCs with platelet-derived growth factor (PDGF) induces autophagy which results in 
decreased expression of contractile proteins and increased synthetic protein markers, thereby 
promoting a synthetic VSMCs phenotype. Pharmacological inhibition of autophagy by 3-
methyladenine or spautin-1 stabilizes the contractile phenotype and prevents PDGF-induced 
VSMCs proliferation (74). Interestingly, Atg7-deficient VSMCs show increased collagen content 
and elevated migration potential, which provides a novel link between autophagy and VSMCs 
phenotype switching (72). A recent study uncovers a link between autophagy and VSMCs 
senescence, a process that irreversibly makes cells lost proliferation potential. Atg7-deficient 
VSMCs exhibit elevated p62 protein and mRNA levels, which induce p16/RB-mediated 
senescence and promote atherosclerosis (72).  
1.2.2 Autophagy and mitophagy in the heart 
            The heart is rich in mitochondria and is susceptible to cellular damage caused by 
dysfunctional mitochondria. Therefore, general autophagy or mitophagy-mediated mitochondria 
clearance has been intensively studied by researchers in this field. Nakai and colleagues report 
that at the basal level, Atg5 cardiomyocyte-specific knock out mice develop cardiac hypertrophy, 
left ventricular dilatation and contractile dysfunction (75). A more recent study indicates that 
genetic Pink1 global knock out induces early left ventricular dysfunction and cardiac 
hypertrophy by increasing oxidative stress and impairing mitochondrial function (76). 
Nevertheless, Beclin1+/- and Parkin global knock out mice do not exhibit cardiac dysfunction 
(77,78). Moreover, Mfn2 cardiac-specific knock out mice, a model of impaired mitochondria 
fusion, present accumulating abnormal mitochondria by interrupting PINK1/Parkin-mediated 
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mitophagy (17). These studies suggest that general autophagy and mitophagy play a vital role in 
maintaining normal cardiac structure and function.  
            Under cardiac stress conditions, activation of autophagy seems to have a protective 
effect. Suppression of autophagy is detrimental in Beclin1+/- mice subjected to chronic 
myocardial infarction (MI) and ischemia-reperfusion (I/R) (78). I/R-dependent activation of 
autophagy is associated with upregulation of multifunctional prosurvival molecule, Bcl-2-
associated athanogene (79). In addition, the autophagic vacuoles are large and contain degraded 
mitochondria in the border zone, while the remote zone contains normal-sized autophagosomes 
(80). Intensive studies show that mitophagy also plays a protective role under cardiac stress 
conditions. Parkin knock out mice have reduced survival rates and develop larger infarcts after 
MI (77). Loss of Pink1 increases the infarct size after I/R (81). Moreover, AMPKα2-induced 
PINK1 S495 phosphorylation activates mitophagy and prevents heart failure (HF) in patients and 
mouse model of transverse aortic constriction (TAC) (82). These studies suggest that 
PINK1/Parkin-mediated mitophagy is important in protecting cardiomyocytes against cardiac 
stress. Another study indicates that both Bnip3 and Nix cardiac-specific knock outs accelerate 
cardiac hypertrophy and mitochondrial dysfunction in mice (83). FUNDC1, a mitophagic 
receptor, has been found to regulate mitochondrial homeostasis and protect the heart from I/R 
injury (84,85). Taken together, these studies suggest that autophagy and mitophagy are important 
in protecting the heart against various stresses.  
1.2.3 Autophagy and mitophagy in atherosclerosis 
          Atherosclerosis is a chronic inflammatory disease which remains the leading cause of 
death in the developed world. It is characterized by the formation of lipid-containing plaques in 
large- and medium-sized arteries. There are three major types of cell in atherosclerotic plaques, 
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including VSMCs, ECs, and inflammatory cells (such as macrophages) (86,87). Rupture of 
plaques is the main cause of acute cardiovascular events. The mechanisms underlying plaque 
rupture may involve foam cell formation, endothelial dysfunction, VSMCs phenotype switching, 
and inflammation (88). During plaque formation, autophagy is stimulated in all three cell types 
of atherosclerotic plaques, as evidenced by transmission electron microscopy (TEM) analysis. It 
is suggested that atherosclerosis largely induces the formation of autophagosomes containing 
amorphous materials, which are rarely observed under normal conditions (89). These findings 
are also supported by western blot analysis of lysates from advanced human plaques, which 
indicate elevated levels of LC3-II (90).  
           Macrophages are known to play a pivotal role in atherosclerosis and macrophage 
autophagy is important in inhibiting the process of atherosclerosis. Macrophage autophagy is 
involved in the clearance of cholesterol deposits in vascular tissue at early stages. Reverse 
cholesterol transport is a pivotal pathway involved in the return of excess cholesterol from 
peripheral tissues to the liver for excretion in the bile (91). Atg5-deficient macrophages show 
reduced efflux of cholesterol. Increased protein levels of mTOR and phospho-mTOR are found 
in Atg5-deficient macrophage-derived foam cells. Inhibition of mTOR with siRNA suppresses 
foam cell formation, which indicate activation of autophagy promotes cholesterol efflux and 
inhibits the formation of atherosclerotic plaques (92). Macrophage autophagy also plays a 
protective role in the development of atherosclerosis. In macrophage-specific Atg5 deletion 
LDLR-/- mice, autophagy deficiency enhanced the total necrotic area in advanced atherosclerotic 
plaques due to an increasing oxidative stress caused by augmented macrophage apoptosis (93). 
Autophagy deficiency is associated with NLRP3 inflammasome hyperactivation, which further 
promotes atherosclerosis progression (94). In addition, macrophage-specific TFEB transgenic 
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mice exhibit enhanced autophagy and reduced atherosclerosis by promoting aggrephagy of p62-
enriched protein aggregates, blunting macrophage apoptosis, and reducing pro-inflammatory IL-
1β levels (95). Taken together, these studies provide evidence that macrophage autophagy 
protects against atherosclerosis progression. 
1.2.4 Autophagy and mitophagy in diabetic cardiomyopathy 
            Diabetes mellitus is a devastating disease, affecting 34.2 million people in the United 
States (10.5% of the population) and more than 347 million people worldwide (according to 
National Diabetes Statistics Report, 2020, Centers for Disease Control and Prevention). Type 2 
diabetes is the most common form of diabetes, affecting 90% to 95% of all patients with 
diabetes. Diabetic cardiomyopathy develops in the absence of traditional risk factors, such as 
coronary artery disease, uncontrolled hypertension, significant valvular heart disease, and 
congenital heart disorders (96). The prevalence of cardiomyopathy increases from 3% to 12% in 
diabetic patients, which is a major cause of heart failure in patients with Type 2 diabetes (97). 
Multiple factors, such as hyperglycemia, insulin resistance, and increased fatty acids, may 
collectively contribute to the development of diabetic cardiomyopathy. Here, we will focus on 
the effect of autophagy and mitophagy on the development of diabetic cardiomyopathy. 
            Mitochondria are essential for energy production, but if damaged, they become a major 
source of reactive oxygen species (ROS) and pro-apoptotic factors. Increasing evidence suggests 
that damaged mitochondria leads to the increased sustainment of ROS which is a central event in 
the development of diabetic cardiomyopathy (98). Therefore, mitochondria quality control 
through autophagy and mitophagy is an important mechanism to maintain mitochondrial 
homeostasis and preserve cell viability. Xie et al. report that autophagy is suppressed in mouse 
hearts with type 1 diabetes, including OVE26 and STZ-induced diabetic mouse models, because 
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hyperglycemia inhibits AMPK. The suppression of autophagy contributes to the development of 
diabetic cardiomyopathy is supported by the evidence that metformin, an AMPK activator, can 
rescue autophagic activity, and concomitantly ameliorates diabetic cardiomyopathy (99,100). 
Another group shows that inhibited autophagy in STZ-induced diabetic mouse model is due to an 
increase in MTORC1 activity. However, they think this is an adaptive response to prevent 
excessive autophagic degradation of cellular components (101). In addition, Kobayashi et al. 
demonstrate that hyperglycemia induced suppression of autophagy is a beneficial adaptive 
response against high glucose toxicity in cultured cardiomyocytes (102).  
            Compare to type 1 diabetes, the results from type 2 diabetes are controversial due to 
different animal models and different criteria for autophagy. For example, activation of 
myocardial autophagy is associated with systemic insulin resistance in fructose-fed mice (103).  
Expression of autophagy marker LC3B-II and Beclin1 significantly increases in the specimens 
from diabetic and non-diabetic patients subjected to coronary artery bypass graft surgery, 
suggesting that autophagy is activated in type 2 diabetic heart (104). By contrast, high-fat diet 
(HFD)-fed mice exhibit inhibition of cardiac autophagy (105,106). Taken together, these results 
suggest that mitochondria quality control by autophagy/ mitophagy is important in protecting 
against diabetic cardiomyopathy.  
1.3 Objectives 
            The goal of this dissertation is to identify the novel signaling regulations of autophagy 
and mitophagy pathways and investigate how these processes contribute to the development of 
cardiovascular diseases, which are the major cause of deaths world-wide. In this light, all the 
presented studies have been designed to be translational applicable in the context of 
cardiovascular diseases. Focusing on two common diseases in the cardiovascular system, 
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atherosclerosis and diabetic cardiomyopathy, this dissertation can be divided into two parts. Part 
1 is to investigate the alterations of autophagy activity in regulating microtubule stability and 
VSMCs migration, which facilitates early lesion development in atherosclerosis (107). Part 2 is to 
investigate the role of mitophagy in diabetic cardiomyopathy and find the potential therapeutic 
strategy. 
            Autophagy is an intracellular quality control pathway in which long-lived proteins and 
organelles are delivered to lysosomes for degradation and recycling. Although autophagy has 
been considered a non-specific degradation process, increasing evidence demonstrates that 
autophagy is also critical for the degradation of specific cargoes such as organelles and proteins 
(108). Tubulin acetylation was first described 20 years ago, but little is known about the enzymes 
that catalyze this reaction. The role of tubulin acetylation on microtubule stability and VSMCs 
migration are still poorly understood. Using in vitro cell culture system, autophagy-defective 
atg5-/- and atg7-/- MEFs and hASMCs, we systemically investigated how autophagy regulates the 
enzyme that catalyzes tubulin acetylation, how tubulin acetylation affects microtubule stability, 
and how microtubule stability influences VSMCs migration. 
            Diabetes mellitus is a devastating disease, affecting 30.3 million (9.4%) people in the 
United States. Type 2 diabetes is the most common form of diabetes, affecting 90% to 95% of 
total patients (109). The prevalence of diabetic cardiomyopathy is increasing in parallel with the 
increase in diabetes mellitus (110,111). Despite its high prevalence, a specific strategy to prevent 
or treat diabetic cardiomyopathy has not been established. BET family protein BRD4 can 
facilitate transcriptional activation or suppression of genes by associating with acetylated 
chromatin. In 2010, two different groups firstly discovered JQ1 and I-BET, the BET 
bromodomain inhibitors (112,113). Since then, the BET inhibitors have been reported to exert 
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anti-cancer, immunosuppressive, and anti-hypertensive effects (114). However, the effects of 
BET inhibitors on diabetic cardiomyopathy remains unknown. We generated diabetic 
cardiomyopathy mouse model by feeding two-month-old C57BL/6J mice with normal diet (ND) 
or high-fat diet (HFD) for six months. Using comprehensive approaches, including primary cell 
culture, pharmacological intervention mouse model, and gene knockout mouse model, this work 
aims to provide insight into the expansion of therapeutic usage of BET inhibitors in 
cardiovascular system and delineate the underlying molecular mechanisms. 
            In summary, using a wide selection of biological and biochemical techniques including 
western blotting, confocal imaging, real-time PCR, ChIP-qPCR, plasmids/siRNA transfection, 
flow cytometry etc., this dissertation is designed to investigate the role of autophagy and 
mitophagy in the cardiovascular system. The accomplishment of this work will provide valuable 
references to design strategies to treat cardiovascular diseases, especially atherosclerosis and 
diabetic cardiomyopathy. 
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1.5 Tables and Figures 
 
 
 
 
Figure 1.1 Schematic model of autophagy 
Autophagy induction is controlled by the ULK1 complex, which consists of ULK1, Atg13, FIP200 and 
Atg101. Nutrient deprivation generally activates AMPK pathway, which activates ULK1 complex. 
Excess amino acid and insulin/insulin-like growth factors generally activates MTORC1, which inhibits 
ULK1 complex. The activated ULK1 complex can regulate class III PtdIns3K complex at PAS, which is 
responsible for the nucleation of the phagophore membrane. Then Atg12–Atg5 and LC3–PE conjugates 
are recruited to the phagophore to facilitate the phagophore membrane expansion. Once the 
autophagosome forms, most of the Atg proteins are dissociated from the surface of autophagosome, 
allowing fusion of autophagosome and lysosome and cargo degradation by lysosomal proteases. 
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Figure 1.2 Schematic model of mitophagy. 
Mitochondrial dysfunction causes PINK1 accumulation on the surface of the mitochondria, where it 
phosphorylates ubiquitin (Ub) and recruits Parkin from cytosol to mitochondria. Parkin further 
ubiquitinates some outer mitochondria membrane (OMM) proteins. The adaptor protein p62 binds 
ubiquitin and autophagosomal LC3 to anchor mitochondria to the autophagosome. OMM proteins such as 
BNIP3, BNIP3L/NIX, FUNDC1, and Bcl2-L-13 bind to LC3 on autophagosome membrane independent 
of ubiquitin and adaptor protein p62.  
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2.1 Abstract 
Macroautophagy/autophagy, a fundamental process for degradation of macromolecules 
and organelles, occurs constitutively at a basal level and is upregulated in response to stress. 
Whether autophagy regulates protein acetylation and microtubule stability in vascular smooth 
muscle cells (VSMCs) migration, however, remains unknown. Here, we demonstrate that the 
histone acetyltransferase KAT2A/GCN5 (lysine acetyltransferase 2) binds directly to the 
autophagosome protein MAP1LC3/LC3 (microtubule associated protein 1 light chain 3) via a 
conserved LC3-interacting region (LIR) domain. This interaction is required for KAT2A 
sequestration in autophagosomes and degradation by lysosomal acid hydrolases. Suppression of 
autophagy results in KAT2A accumulation. KAT2A functions as an acetyltransferase to increase 
TUBA/α-tubulin acetylation, promote microtubule polymerization and stability, ultimately 
inhibiting directional cell migration. Our findings indicate that deacetylation of TUBA and 
perturbation of microtubule stability via selective autophagic degradation of KAT2A are 
essential for autophagy-promoting VSMC migration. 
2.2 Introduction 
Cell migration is a central process in the development and maintenance of multicellular 
organisms. In an adult organism, cell migration is involved in tissue renewal, immune response, 
and wound repair, and aberrant cell migration is found in various pathologies, including vascular 
disease, chronic inflammatory diseases, and tumor metastasis. In the vasculature, migration of 
vascular smooth muscle cells (VSMCs) from the media to intima occurs during the development 
of intimal hyperplasia and atherosclerosis (1,2). Microtubules are essential components of the 
cytoskeleton and play a major role in cell migration (3). These polarized polymers are composed 
of α- and β-Tubulin. Microtubules alternate between phases of growth and shrinkage in a manner 
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described as dynamic instability (4). Maintaining the balance between dynamically unstable and 
stable microtubules is required for cell migration. Microtubule stability is regulated by various 
microtubule-associated proteins and posttranslational modifications, including acetylation, 
polyglutamylation, and detyrosination. These modifications appear to fine-tune the properties of 
tubulin and microtubules to facilitate their diverse functions. Acetylation of microtubules in 
mammalian cells is positively regulated by a variety of acetyltransferases, including, but not 
limited to, ATAT1 (alpha tubulin acetyltransferase 1) and the elongator protein complex (5,6). 
To date, the histone deacetylase (HDAC) family member HDAC6 (histone deacetylase 6) and 
SIRT2 (sirtuin 2) are the only TUBA deacetylases to be described (7,8); however, the enzymes 
that are responsible for regulating tubulin acetylation and deacetylation in VSMCs remain 
unknown. Although acetylation of TUBA is always associated with stable microtubules, the 
precise role of TUBA acetylation in the regulation of microtubule dynamics and cell migration in 
VSMCs has not been resolved. 
Autophagy is a catabolic process that plays a pivotal role in metabolism, cell death, and 
differentiation (9,10). During autophagy, cytoplasmic components, including long-lived proteins 
and organelles, are engulfed by a double-membrane structure and targeted for destruction in 
lysosomes (11). Autophagy initiation requires the activation of ULK1 (unc-51 like autophagy 
activating kinase 1) and the class III phosphatidylinositol 3-kinase (PtdIns3K)-BECN1 (beclin 1) 
complex. Once activated, the ULK1 complex drives initiation of autophagosome formation. 
Elongation and maturation of autophagosomes are regulated by two well-conserved conjugation 
systems, the conjugation of ATG12 to ATG5 with the help of ATG7 and ATG10 and the 
conjugation of phosphatidylethanolamine (PE) to MAP1LC3/LC3/Atg8 (microtubule-associated 
protein 1 light chain 3) by the sequential action of ATG4, ATG7, and ATG3 (12). The 
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autophagosome then fuses with the lysosome forming autolysosomes within which the cargos are 
degraded by lysosomal acid hydrolases (11).  
Recently, specific autophagic degradation of polyubiquitinated protein aggregates was 
described, and this substrate-specific autophagy also regulates the turnover of small molecules 
and entire organelles within cells (13). Many studies have shown that autophagy can be regulated 
by protein acetylation (14), but whether autophagy can regulate protein acetylation remains 
unknown. Alterations in autophagy activity have been reported in numerous vascular diseases 
including pulmonary hypertension (15), vascular aging (16), atherosclerosis (17), and restenosis 
(18). However, further investigation is required to delineate the mechanism by which autophagy 
regulates microtubule stability and cell migration and determine the roles of autophagy in 
vascular diseases. In this study, we demonstrate that activation of autophagy selectively degrades 
KAT2A, a histone acetyltransferase that acetylates TUBA in VSMCs, leading to microtubule 
instability and promotion of VSMC migration.  
2.3 Materials and methods 
2.3.1 Reagents 
            Antibodies and reagents are from the following companies: ATG5 (Cell Signaling 
Technology, 8540), ATG7 (Cell Signaling Technology, 8588), SQSTM1/p62 (abcam, 56416), 
BECN1 (Cell Signaling Technology, 3738), TUBA/α-Tubulin (Cell Signaling Technology, 
3873), MAP1LC3A/B (Cell Signaling Technology, 4108), ULK1 (Cell Signaling Technology, 
8054), KAT2A/GCN5 (abcam, 137515), acetylated-lysine (Cell Signaling Technology, 9441), 
MYC-tag (Cell Signaling Technology, 2276), HDAC6 (Cell Signaling Technology, 7612), 
SIRT1 (Cell Signaling Technology, 9475), mouse secondary antibody (Cell Signaling 
Technology, 7076), rabbit secondary antibody (Cell Signaling Technology, 7074), ACTB/β-actin 
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(Santa Cruz Biotechnology, 47778), EP300 (Santa Cruz Biotechnology, 48343), GAPDH (Santa 
Cruz Biotechnology, 32233), Flag (Sigma-Aldrich, 7425), GFP (Sigma-Aldrich, 1544), goat 
anti-mouse IgG conjugated to Alexa Fluor 594 red (ThermoFisher Scientific, 11032), goat anti-
rabbit IgG conjugated to Alexa Fluor 555 red (ThermoFisher Scientific, 21434), anti-TUBA 
(Acetyl K40) antibody [6-11B-1] (abcam, 24610). EnVision® + Dual Link System-HRP (DAB+) 
(Dako Cytomation, 3468). The recombinant KAT2A/GCN5-catalytic domain (362-837) protein 
(Active Motif, 31204). Purified porcine brain tubulin protein (>99% pure) (Cytoskeleton Inc., 
T240). Recombinant human GST-LC3 protein and GST protein (Enzo Life Sciences, BML-
UW1195-0500). KAT2A/GCN5 siRNA (Santa Cruz Biotechnology, 37946), ULK1 siRNA (Santa 
Cruz Biotechnology, 44849), ATG7 siRNA (Cell Signaling Technology, 6604), ATG5 siRNA 
(Cell Signaling Technology, 6345), SQSTM1 siRNA (Cell Signaling Technology, 6399). The 
siRNA delivery reagent Lipofectamine RNAiMAX (Life Technologies, 13778150), 
Lipofectamine® 2000 (Life Technologies, 11668019). Nocodazole (Sigma-Aldrich, 31430), 
chloroquine (Sigma-Aldrich, 6628), lactacystin (Sigma-Aldrich, 6785). 
2.3.2 Plasmids and construction 
Plasmids were obtained from Addgene (Cambridge, MA): EGFP-TUBA WT (30487, 
Tso-Pang Yao’s lab), EGFP-TUBAK40R (64059, Weiping Han’s lab), Myc-LC3 (24919, Toren 
Finkel’s lab), EGFP-LC3 (11546, Karla Kirkegaard’s lab). Flag-KAT2A plasmid was a gift from 
Dr. Ezra Burstein (Internal Medicine, UT Southwestern Medical Center). To identify the 
interaction between LC3 and KAT2A, a series of KAT2A deletion was constructed by site-
directed mutagenesis using a QuikChange II Kit (Stratagene, La Jolla, CA) according to the 
manufacturer's protocol. The primers used for the deletions were as follows: KAT2AΔ1 (deletion 
of 661 bp - 664 bp) forward 5’- gcatcccctcccacatcatca -3’, reverse 5’- gcatcccctcccacatcatca -3’; 
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KAT2AΔ2 (deletion of 716 bp - 719 bp) forward 5’- agagacaggcgggaaggagaagggga -3’, reverse 
5’- tcccgcctgtctctcgaatgccag -3’; KAT2AΔ3 (deletion of 734 bp - 737 bp) forward 5’- 
cgaccagctcaaaaacctgctg -3’, reverse 5’- gtttttgagctggtcggggtccttcagc -3’; KAT2AΔ4 (deletion of 
826 bp - 829 bp) forward 5’- agttcttcaaggagggaggcctcat -3’, reverse 5’- 
ccctccttgaagaacttctccagggcgctg -3’. In addition, a double-site-mutant (Y734A, L737A) was 
constructed by multiple site-directed mutagenesis using QuikChange Multi Site-Directed 
Mutagenesis Kit (#200514. Agilent Technologies) according to the manufacturer's protocol with 
the following primers: 5’- cagctcgccacaaccgccaaaaacctg-3’ and 5’- gtttttggcggttgtggcgagctggtcg-
3’. All plasmids were confirmed by sequencing.  
2.3.3 Cell culture and transfection 
The atg5-/- and atg7-/- mouse embryonic fibroblasts (MEFs) were a kind gift from Dr. 
Masaaki Komatsu (The Tokyo Metropolitan Institute Medical Science, Tokyo, Japan). MEFs, 
HEK293 (ATCC, CRL-1573), and HeLa (ATCC, CCL-2) cells were maintained in Dulbecco’s 
Modified Eagle’s Media (DMEM) (Corning, 10-017-CV), supplemented with 10% fetal bovine 
serum (FBS) (Sigma, F0926). Human aortic smooth muscle cells (HASMCs) was purchased 
from Invitrogen (Life Technologies, C-007-5C)) and maintained in Medium 231 (ThermoFisher 
Scientific, M231500) supplemented with 5% smooth muscle cell growth supplements (Sciencell, 
1152). During the migration experiment, HASMCs were cultured in complete DMEM medium. 
All culture media were supplemented with penicillin (100 U/ml) and streptomycin (100 µg/ml) 
(ThermoFisher Scientific, 15140163). Cultured cells were incubated in a humidified atmosphere 
of 5% CO2 and 95% ambient air at 37°C. 
  ATG5, ATG7, and BECN1 siRNA were obtained from Cell Signaling. For siRNA 
depletion, HASMCs or MEFs were plated in 6-well plates. After reaching 70% confluence, the 
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cells were treated with the indicated siRNA at a final concentration of 50 nM using 
Lipofectamine RNAiMAX reagent (Life Technologies, 13778150) in serum-free medium. After 
6 h, the medium was removed and replaced with fresh medium containing 10% FBS. The cells 
were incubated in the fresh medium for 48 h. HeLa and HEK 293 cells were transfected with 2.5 
μg plasmids using Lipofectamine 2000 (Life Technologies, 11668019). HASMCs and MEFs 
were electroporated with 2.5 μg plasmids using the 4D-NucleofectorTM System (Lonza, Frazer, 
PA, USA) according to the manufacturer’s instructions. ATG5 adenovirus was purchased from 
SignaGen Laboratories (Rockville, MD, USA). ATG7 adenovirus was a gift from Dr. Jeffrey 
Robbins (Department of Pediatrics, The Cincinnati Children’s Hospital Medical Center, 
Cincinnati, OH, USA). The adenoviruses encoding short hairpin KAT2A RNA (sh-KAT2A) or 
KAT2A were a gift from Dr. Pere Puigserver (Department of Cell Biology, Harvard Medical 
School, Boston, MA, USA). The adenoviruses were amplified in HEK293 cells and purified by 
CsCl2 density gradient ultracentrifugation. Cells were infected with adenovirus at a multiplicity 
of infection of 100 for 2 h, and then medium was replaced with fresh normal medium. Protein 
expression was detected 48 h after transfection via immunoblotting analysis with specific 
antibodies. 
2.3.4 Autophagy analysis 
Autophagy activity was assessed by measuring GFP-LC3 puncta formation, LC3 
cleavage, and SQSTM1 degradation. To determine autophagosome formation, cells were 
cultured on glass coverslips and allowed to adhere overnight. The cells were transfected with 
GFP-LC3 adenovirus for 24 h and then incubated with 5 μM chloroquine diphosphate (CQ) for 
another 24 h. After treatment, cells were fixed, and fluorescence images were obtained using a 
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fluorescent microscope. Autophagy was measured by enumerating the average number of 
autophagosomes per cell for each sample. At least 100 cells per sample were counted.  
2.3.5 Real-time PCR analysis 
Total RNA was extracted from cultured cells using RNeasy Mini Kit (Qiagen, Valencia, 
CA). For reverse transcription, 1 µg of the total mRNA was converted to first-strand 
complementary DNA in 20 µL reactions using the iScript cDNA synthesis kit (Bio-Rad 
Laboratories, Hercules, CA). The primers used for amplification of genes were as follows: 
KAT2A (mouse) 5’- CGAGTTGTGCCGTAGCTGTGA-3’ (forward) and 5’- 
ACCATTCCCAAGAGCCGGTTA -3’ (reverse) and GAPDH (mouse) 5’-
CCACTCCTCCACCTTTGAC-3’ (forward) and 5’-ACCCTGTTGCTGTAGCCA-3’ (reverse). 
Quantitative RT-PCR reactions were performed using aiQ™ SYBRGreen SupermixKit and a 
CFX96 real-time PCR detection system (Applied Biosystems, Foster City, CA) as described 
previously (19). Calculations were performed using the comparative method (2-∆∆Ct) with 
GAPDH as an internal control (20). 
2.3.6 Immunoprecipitation and immunoblotting 
            Immunoprecipitation (IP) was performed as described previously (21,22). Briefly, cells 
were collected and lysed in RIPA buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 140 mM 
NaCl, 0.1% SDS, 0.1% sodium deoxycholate, 1% Triton X-100; Sigma, R0278) containing a 
protease inhibitor cocktail (PI; Roche). Protein concentrations were measured with PierceTM 
BCA Protein Assay Kit (ThermoFisher Scientific, 23225). After preclearing with protein A 
agarose beads (GE Healthcare, 17-0780-01) for 30 min at 4°C, whole-cell lysates were subjected 
to IP with the specific antibodies. Generally, 1 µg of antibody was added to 500 µg of cell lysate 
and incubated overnight at 4°C. After incubation with protein A agarose beads for 6 h, 
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immunoprecipitates were eluted with SDS loading buffer by boiling for 10 min. The 
immunoprecipitated proteins were subjected to immunoblotting analysis. 
            For immunoblotting, cells were lysed in RIPA buffer containing a protease inhibitor 
cocktail as described previously (23,24). Protein concentrations were measured with PierceTM 
BCA Protein Assay Kit and lysates containing equal amounts of proteins were separated by 
SDS-PAGE and then transferred to nitrocellulose membranes. The membranes were blocked 
with 5% non-fat dry milk (LabScientific, M0841) and incubated with specific primary antibodies 
overnight at 4°C followed by secondary antibodies. All antibodies were used at the 
manufacturers' recommended dilutions. Immunoreactive bands were visualized by Super 
SignalTM West Pico PLUS chemiluminescent substrate (ThermoFisher, 34580) using an Odyssey 
scanner (LI-COR Biosciences, Bad Homburg, Germany) and Photoshop software. For 
quantification, the protein band intensities of the western blotting images were quantified with 
Alpha view software (ProteinSimple, San Jose, CA). Data are represented as mean intensity of 
bands from at least three independent experiments. The membranes were then stripped and 
probed for total protein and/or ACTB/β-actin to verify equal loading (23,24). 
2.3.7 In vitro affinity-isolation assay 
Glutathione S-transferase (GST) fusion proteins were immobilized on glutathione 
Sepharose 4 Fast Flow beads (GE Healthcare, 1707560) for 30 min at 4°C. For GST affinity 
isolation with purified His-tagged KAT2A protein, 4 μg of GST-LC3 protein was incubated with 
1 μg of KAT2A protein in 500 μl of binding buffer (50 mM Tris-HCl, pH 8.0; 250 mM NaCl) 
for 120 min at 4°C and then washed 5 times with 1 ml of binding buffer. For GST affinity 
isolation in HeLa cell lysates, 4 μg of GST fusion proteins were incubated with 1,000 μg of 
HeLa cell lysate for 2 h at 4°C and then washed 5 times with 1 ml of lysis buffer. The precipitate 
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complex was boiled with 2x Laemmli Sample Buffer (Bio-Rad) containing 1% SDS for 5 min at 
95°C (25) and subjected to SDS-PAGE. After transfer to nitrocellulose membranes (Bio-Rad, 
1620112), proteins were stained with Ponceau S (Sigma, P3504), followed by immunoblotting 
with the indicated antibodies. 
2.3.8 In vitro tubulin acetylation assay 
Purified porcine brain tubulin protein (>99% pure) was incubated with recombinant 
KAT2A-catalytic domain protein (362-837) protein in acetylation buffer (50 mM Tris, pH 8.0; 
50 mM EDTA (Sigma, ED4SS); 10% glycerol; 20 μM acetyl CoA; 10 mM sodium butyrate 
(Sigma, B5887); 10 mM TSA (SELLECKCHEM, S1045); 1 mM GTP) at 37°C for 1 h. The 
acetylation of TUBA was assessed by western blotting. 
2.3.9 Immunofluorescence 
Cells were grown on glass coverslips, fixed with 4% paraformaldehyde for 15 min, and 
permeabilized with 0.2% Triton X-100 (Sigma, T8787) for 15 min. After blocking with goat 
serum, the cells were incubated with TUBA antibody (1:2000 dilution) and acetyl-TUBA 
antibody (1:300 dilution), followed by incubation with fluorescein conjugated secondary 
antibodies. Slides were mounted with Prolong Gold containing DAPI (Invitrogen) and analyzed 
with an Olympus microscope or LSM 510 Zeiss confocal microscope. 
2.3.10 Microtubule depolymerization 
The microtubule depolymerization experiments were performed as described previously 
(26). Briefly, cells were incubated at 0°C for 5, 10, 15 or 30 min. The morphology of 
microtubules was then examined by immunostaining of TUBA and confocal microscope.  
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2.3.11 Nocodazole washout assay 
To analyze nocodazole-induced microtubule depolymerization, cells were treated with 10 
μM nocodazole for 30 min, and then the cells were washed with pre-warmed PBS (Sigma, 
D5652) and pre-warmed media and incubated in pre-warmed media without nocodazole for the 
indicated times. Cell lysates were analyzed by western blot using the indicated antibodies. In 
addition, cells grown on glass coverslips were incubated in growth media with 10 µM 
nocodazole for 30 min, and then the drug was washed out to allow the microtubules to 
repolymerize for the indicated times. The cells were fixed by immersion in ice-cold methanol 
and processed for immunofluorescence analysis. 
2.3.12 Scratch wound healing assay 
            Monolayer smooth muscle cell migration was performed as described previously (27). 
Briefly, HASMCs were plated on glass coverslips in 6-well plates at a concentration of 2.5 x 105 
cells/well and transfected with either siRNA or adenovirus. Forty-eight hours later, a linear 
wound was gently made in the center of the confluent cell monolayer with a 200-μl pipette tip. 
The cells were then washed with fresh medium to remove the cellular debris. Repeated 
observations of the edge of the same scratched lesion were performed. After 10 h, images were 
captured using a microscope (IX71, Olympus) equipped with a digital camera. The distance of 
the gap closure was calculated as the total distance of the gap closed over the migration time. For 
analysis of cell polarity, the cells were fixed and immunostained with a TUBG/γ‑tubulin 
antibody. The angles (θ) of each cell to the scratched line were measured as described by Nakano 
(25). Briefly, line A was drawn from the point stained with a TUBG antibody to the center of the 
nucleus, line B was drawn from the center of the nucleus to the scratched line, and the angles (θ) 
between lines A and B were measured. 
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2.3.13 Transwell migration assay 
            Cell migration was examined using a transwell fitted with polycarbonate membrane (8-
μm pore size, Corning Inc., Corning, NY). Briefly, growth-arrested HASMCs were trypsinized 
and resuspended at a concentration of 1x106 cells/ml in DMEM supplemented with 0.5% FBS. 
HASMC suspension (100 μl) was placed in the upper chamber, and 500 μl of DMEM containing 
10% FBS was placed in the lower chamber. Cells were allowed to migrate through the pores of 
the membrane for 6 h at 37°C in the presence of 5% CO2. The filter was then removed and fixed 
in 4% paraformaldehyde. The cells on the upper side of the filter were scraped off with a cotton 
swab, and the cells that migrated to the lower surface of the filter were stained with 0.2% Crystal 
violet (ThermoFisher Scientific, C581-100) in 10% methanol for 30 min. The chambers were 
washed thoroughly with water, and the cells on the lower surface of filters were counted using a 
light microscope. The experiments were performed at least three times in each group, and cell 
motility is presented as the number of migrated cells/field. 
2.3.14 Statistical analysis 
Data are presented as mean ± SEM. The differences between two groups were analyzed 
using the Student’s t-test. Comparisons between multiple groups were performed using one-way 
analysis of variance (ANOVA) followed by Bonferroni post-hoc analysis. A value of P<0.05 
was considered statistically significant. 
2.4 Results 
2.4.1 Suppression of autophagy increases TUBA acetylation 
Starvation-induced autophagy in mouse embryonic fibroblasts (MEFs) is coupled to 
reduction of histone H4 lysine 16 acetylation (H4K26ac) (28), prompting us to investigate 
whether autophagy regulates protein acetylation. We first analyzed the protein acetylation profile 
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in wild-type (WT) MEFs as well as in MEFs deficient for key autophagy genes (atg5-/- and atg7-
/- MEFs) (29,30). Defective autophagy was verified in atg5-/- and atg7-/- MEFs, as evidenced by 
both reduced conversion of LC3-I to LC3-II (a phosphatidylethanolamine derivative of LC3-I) 
and increased SQSTM1/p62 (sequestosome 1) (a receptor for cargo destined to be degraded by 
autophagy) levels (Fig. 2.1A). The suppression of autophagy was associated with higher levels 
of acetylated proteins (Fig. 2.2A).  
We further determined whether activation of autophagy reduces protein acetylation by 
starvation of MEFs with Hank's buffered salt solution (HBSS) (Fig. 2.1B), which is typically 
used as a trigger of autophagy (31). Starvation significantly increased the conversion of LC3-I to 
LC3-II and reduced SQSTM1 levels (Fig. 2.1B), indicating activation of autophagy. This 
increase in autophagy was accompanied by significant reduction in acetylated protein levels 
(Fig. 2.2B). 
To determine whether autophagy regulates protein acetylation in non-MEF cells such as 
VSMCs, we examined protein acetylation in human aortic smooth muscle cells (HASMCs). In 
line with our findings in MEFs, gene silencing of either ATG5 or ATG7 suppressed autophagy by 
reducing LC3-II levels and increasing SQSTM1 levels (Fig. 2.1C), while concomitantly 
elevating levels of acetylated proteins (Fig. 2.2C). Conversely, activation of autophagy by 
starvation (HBSS treatment) increased conversion of LC3-I to LC3-II and reduced SQSTM1 
levels (Fig. 2.1D), in concurrence with significant reduction in acetylated protein levels (Fig. 
2.2D).  
We noted a band with a molecular weight of ∼50 KD that was significantly increased in 
autophagy-deficient cells (Fig. 2.2A and C). In contrast, this protein was reduced in MEFs and 
HASMCs upon activation of autophagy (Fig. 2.2B and D). Given that a 51-KD TUBA species 
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has been reported to be acetylated and associated with microtubule stability and cell motility (8), 
we examined whether inhibition of autophagy promotes the acetylation of TUBA. Using an 
antibody against acetylated-TUBA (anti-TUBA [acetyl K40] antibody [6-11B-1]), we observed 
that acetylation of TUBA significantly increased in autophagy-deficient atg5-/- and atg7-/- MEFs 
(Fig. 2.2E). Similarly, suppression of autophagy in HASMCs by gene silencing of either ATG5 
or ATG7 also enhanced the levels of acetylated TUBA (Fig. 2.2G). On the contrary, activation of 
autophagy by starvation reduced acetylated TUBA levels in both MEFs and HASMCs (Fig. 2.2F 
and H).  
Since autophagy can occur through either the ATG5/ATG7-dependent conventional 
pathway or the ATG5/ATG7-independent alternative pathway (32), we further explored our 
hypothesis that autophagy regulates acetylation following inhibition of autophagy using siRNA 
against BECN1 and ULK1, two proteins that are required for the activation of autophagy through 
either ATG5/ATG7-dependent or ATG5/ATG7-independent pathway (32). Suppression of 
autophagy by silencing either BECN1 or ULK1 (Fig. 2.1E and F) also increased acetylated 
TUBA levels (Fig. 2.2I and J). Collectively, these data indicate that autophagy negatively 
regulates TUBA acetylation. 
2.4.2 Inhibition of autophagy increases KAT2A protein expression 
To gain insight into the mechanisms by which autophagy regulates TUBA acetylation, 
we examined whether autophagy regulates the expression of acetyltransferases, KAT2A, 
KAT8/hMOF (lysine acetyltransferase 8), EP300, ATAT1, and deacetylases (HDAC6, SIRT1, 
and SIRT2) in HASMCs. Transfection of HAMSCs with ATG5, ATG7, BECN1, or ULK1 siRNA 
resulted in lower levels of ATG5, ATG7, BECN1, or ULK1 respectively, inhibited the 
conversion of LC3-I to LC3-II, and increased SQSTM1 protein level (Fig. 2.1C-F, Fig. 2.3A). 
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Suppression of autophagy was associated with an increase in KAT2A protein levels (Fig. 2.4A-
C, Fig. 2.3A and B), but the suppression of autophagy by ULK1 siRNA did not affect the 
expression of ATAT1, KAT8, EP300, HDAC6, SIRT1 or SIRT2 (Fig. 2.3B).  
Next, we determined if autophagy activation by HBSS treatment leads to changed 
expression of any HDACs including ATAT1, KAT8, EP300, SIRT1 or SIRT2. Activation of 
autophagy reduced KAT2A protein level but has no effects on the expression of ATAT1, KAT8, 
EP300, SIRT1, and SIRT2 (Fig. 2.3C). We also examined the expression of other HDACs, 
including HDAC4, HDAC5, HDAC6, HDAC7, and HDAC9, in the autophagy activation (HBSS 
treatment) condition. The activation of autophagy did not alter the expression of these HDACs 
either (Fig. 2.3D). 
We further validated the effect of autophagy on KAT2A expression in WT, atg5-/-, and 
atg7-/- MEFs and found that deletion of either Atg5 or Atg7 significantly increased KAT2A 
protein expression (Fig. 2.4E-G). Notably, defective autophagy had no effect on KAT2A mRNA 
expression (Fig. 2.4D and H), suggesting that autophagy regulates KAT2A at the 
posttranslational level. Conversely, adenovirus overexpression of either ATG5 or ATG7 
increased conversion of LC3-I to LC3-II (Fig. 2.4I and K) and reduced SQSTM1 levels (Fig. 
2.3E and H), in concurrence with significant reduction in KAT2A protein levels (Fig. 2.4I and 
J).  
We further examined whether activation of autophagy by starvation increases KAT2A 
degradation in WT and atg5-/- MEFs. As expected, starvation (HBSS treatment) activated 
autophagy as evidenced by increased LC3-II to LC3-I ratios in WT MEFs (Fig. 2.4L and M), 
and HBSS treatments failed to activate autophagy in atg5-/- MEFs (Fig. 2.4L and M). As 
autophagy was activated in WT MEFs, KAT2A protein levels declined gradually (Fig. 2.4I and 
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N). More specifically, KAT2A was reduced by 50% in these cells after 24 h HBSS treatment 
(Fig. 2.4I and N). In contrast, in autophagy-defective atg5-/- MEFs, HBSS treatment did not alter 
KAT2A levels compared to levels in the vehicle-treated cells (Fig. 2.4I and N), indicating 
KAT2A protein degradation by autophagy was inhibited in atg5-/- MEFs. Similarly, starvation 
also promoted the degradation of exogenous KAT2A in HeLa cells, because following 
transfection of HeLa cells with GFP or Flag-KAT2A plasmid and subsequent starvation by 
incubation of the cells in HBSS, KAT2A levels were decreased in a time-dependent manner 
(Fig. 2.4O). Taken together, autophagy activation promotes KAT2A protein degradation.  
To investigate whether the proteasome is involved in this KAT2A degradation, we 
treated HASMCs with the lysosome inhibitor chloroquine (CQ) (21) or the proteasome inhibitor 
lactacystin (Lacta) (33). CQ treatment resulted in increased levels of LC3-II and SQSTM1 
proteins (inhibition of autophagic flux) in association with an increase in the KAT2A protein 
level (Fig. 2.4P), indicating that defective autophagy reduces KAT2A protein degradation. 
Conversely, proteasome inhibition with Lacta, which exerts no effect on autophagy activity, 
increased protein level of RUNX2 (runt related transcription factor 2), a well-known protein 
degraded by proteasomal pathway (34), but failed to alter KAT2A protein levels (Fig. 2.4P). 
Taken together, these data suggest that KAT2A is degraded through the autophagy-lysosomal 
pathway. 
2.4.3 KAT2A binds to LC3 and co-localizes with autophagosomes 
To confirm our results that suggest autophagic degradation of KAT2A, we examined the 
localization of KAT2A in autophagosomes using immunostaining of KAT2A in HASMCs 
transfected with GFP-LC3 adenovirus as a probe for detection of autophagosome formation. 
Fluorescence microscopy analysis revealed that KAT2A (red) was not only localized in the 
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nucleus but was also distributed in the cytoplasm. Interestingly, some of the KAT2A protein in 
the cytoplasm co-localized with GFP-LC3 puncta (Fig. 2.5A). The co-localization of KAT2A 
and LC3 suggests that these two proteins may interact physiologically with each other.  
To test this possibility, we first examined the interaction between KAT2A and LC3 in 
HeLa cells transfected with EGFP or EGFP–LC3 plasmid. Twenty-four h after transfection, cells 
were collected for immunoprecipitation (IP) with anti-KAT2A antibody and immunoblotting 
with GFP antibody. A band representing GFP-LC3 was detected in the cells transfected with 
EGFP-LC3 and immunoprecipitated with anti-KAT2A but not in the cells transfected with GFP 
(Fig. 2.5B). In addition, glutathione S-transferase (GST)-LC3 beads pulled down recombinant 
full-length KAT2A in binding buffer (Fig. 2.5C), indicating that KAT2A physically associates 
with LC3 in cells.  
We next determined whether SQSTM1 mediates the interaction between KAT2A and 
LC3. In HeLa cells, ectopically overexpressed Myc-LC3 associated with endogenous KAT2A 
(Fig. 2.5D); however, overexpressed Flag-KAT2A did not associate with SQSTM1 (Fig. 2.5E). 
Importantly, gene silencing of SQSTM1 did not disrupt the association between KAT2A and LC3 
in HeLa cells, (Fig. 2.6), suggesting that KAT2A physically interacts with LC3, and SQSTM1 is 
not involved in the interaction between KAT2A and LC3. 
2.4.4 The LC3 interaction region (LIR) domain of KAT2A mediates the association 
of KAT2A with LC3 and is essential for KAT2A degradation 
Next, we investigated whether the LIR domain of KAT2A is required for KAT2A 
degradation. Autophagy receptor proteins, such as NBR1 (NBR1 autophagy cargo receptor), 
SQSTM1, Atg32p, and FUNDC1 (FUN14 domain containing 1), bind to LC3 and LC3 
homologues through an LIR domain that is typified by the core consensus sequence 
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W/F/YxxL/I/V (Fig. 2.7A) (35,36). To determine whether KAT2A is an autophagy substrate, we 
analyzed KAT2A protein sequence for predicted LIR domains and found four candidate LIR 
domains in KAT2A at amino acids 661-664, 716-719, 734-737, and 826-829 (Fig. 2.7B). To 
investigate whether one of these LIR domains mediates the interaction between KAT2A and 
LC3 and to identify which one, we generated a series of LIR domain deletion mutants (Fig. 
2.7C). These mutants were overexpressed in HEK293 cells, and the interaction between KAT2A 
and endogenous LC3 was determined by immunoprecipitation and western blotting. As depicted 
in Figure 2.5F, the mutant with deletion of amino acids 734-737, but not mutants with deletion 
of the other candidate domains at amino acids 661-664, 716-719, and 826-829, completely 
disrupted the interaction between KAT2A and LC3. To further demonstrate that KAT2A 
interacts with LC3 through the LIR (734-737), we mutated Y734 and L737 to alanine and 
overexpressed this mutant in HeLa cells. Immunoprecipitation and western blotting showed that 
altering the sequence at the LIR also completely prevented the interactions between KAT2A and 
LC3 (Fig. 2.5G), indicating that amino acids 734-737 comprise the LIR domain that mediates 
the interaction between KAT2A and LC3.  
To determine whether this KAT2A LIR domain is required for KAT2A degradation by 
autophagy, we expressed WT KAT2A or mutant KAT2A (734-737 deletion) in HEK293 cells. 
After transfection, the cells were subjected to starvation with HBSS. As depicted in Figure 2.5H 
and I, activation of autophagy reduced WT KAT2A protein levels. Deletion of the LIR domain 
of KAT2A amino acids 734-737 abrogated this KAT2A reduction induced by autophagy 
activation (Fig. 2.5H and I). Thus, the LIR domain at amino acids 734-737 of KAT2A is 
required for KAT2A autophagic degradation. 
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2.4.5 KAT2A induces TUBA acetylation 
To investigate whether KAT2A acetylates TUBA, we first examined whether KAT2A 
interacts with TUBA in WT and atg5-/- MEFs. Immunoprecipitation and western blot analysis 
demonstrated that KAT2A associated with TUBA in WT MEFs, and this association was 
enhanced in autophagy-deficient atg5-/- MEFs, due to the accumulation of KAT2A in the cells 
(Fig. 2.8A), indicating that KAT2A specifically interacts with TUBA. Next, we examined 
whether KAT2A directly acetylates TUBA in a cell free system by incubating purified porcine 
brain tubulin protein (>99% pure) with recombinant KAT2A-catalytic domain protein in 
acetylation buffer, we found that the KAT2A-catalytic domain alone was sufficient to induce 
TUBA acetylation, as evidenced by increased acetylated TUBA in the purified porcine brain 
tubulin protein in a dose-dependent manner (Fig. 2.8B).  
We further examined whether KAT2A induces TUBA acetylation in HASMCs using 
gain-of- and loss-of-function approaches. As depicted in Fig. 2.8C-E, the transfection of KAT2A 
siRNA dramatically reduced KAT2A protein levels as well as levels of TUBA acetylation (Fig. 
2.8C-E). Immunofluorescence analysis confirmed that KAT2A gene silencing reduced the levels 
of acetylated TUBA (Fig. 2.8F-H). In contrast, ectopic expression of KAT2A in HEK 293 cells 
resulted in increased levels of acetylated TUBA (Fig. 2.8I and J).  
To date, the most-studied modification of tubulin is acetylation of Lys40 (K40) of TUBA 
(37). Therefore, we examined whether KAT2A induces acetylation of TUBA specifically at 
Lys40. We co-transfected HEK293 cells with KAT2A adenovirus and WT EGFP-TUBA plasmid, 
and acetylation-defective TUBA plasmid (EGFP TUBAK40R) (38). Overexpression of KAT2A 
increased the acetylation of TUBA in the cells transfected with EGFP-WT-TUBA but not in the 
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cells transfected with mutant EGFP-TUBAK40R (Fig. 2.8K), supporting the notion that KAT2A 
acetylates Lys40 of TUBA. 
2.4.6 Autophagy deficiency increases microtubule stability 
Acetylation of TUBA is a well-established marker of more stable microtubules in cells 
(39). We observed that autophagy regulated acetylated TUBA levels (Fig. 2.2) and that 
suppression of autophagy by genetic deletion (atg5-/- and atg7-/- MEFs) or gene silencing (ATG5-
, ATG7-, BECN1-, and ULK1-transfected HASMCs) increased the amount of acetylated TUBA 
(Fig. 2.2E, G, I, and J). On the contrary, activation of autophagy by starvation with HBSS 
decreased TUBA acetylation (Fig. 2.2F and H). We verified the effect of autophagy on 
acetylation of TUBA using immunofluorescence staining of acetylated TUBA in HASMCs 
transfected with ATG7 siRNA (Fig. 2.9A and B), compared with control siRNA treatment, 
ATG7 siRNA transfection significantly increased the abundance of acetylation of TUBA (Fig. 
2.9A and B) but had no effect on the abundance of total TUBA. These effects on TUBA 
acetylation, therefore, suggest that autophagy negatively regulates microtubule stability. 
We further determined the effect of autophagy on microtubule stability by examining the 
morphology of microtubules using immunofluorescence microscopy. HAMSCs were transfected 
with control or ATG7 siRNA and then incubated the cells at 0°C for 5, 10, 15 or 30 min. As 
shown in Figure 2.9C and D, cold treatment resulted in the depolymerization of microtubules in 
a time-dependent manner and microtubules were completely depolymerized after 30 min of cold 
treatment. In contrast, microtubules were still present in cells transfected with ATG7 siRNA (Fig. 
2.9C and D). These data suggest that inhibition of autophagy increased microtubule stability.  
To investigate whether autophagy deficiency affects microtubule assembly, we treated 
both WT and atg5-/- MEFs with nocodazole (0.5 µM) for 30 min to depolymerize microtubules, 
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the drug was then washed out to allow re-polymerization of microtubules. Western blot analysis 
revealed that K40-acetylated TUBA was barely detectable in WT and atg5-/- MEFs following 
nocodazole treatment compared to levels in untreated MEFs; however, the acetylated TUBA 
levels recovered more quickly in atg5-/- MEFs than in WT cells (Fig. 2.9E and F), suggesting 
that autophagy deficiency promotes microtubule reassembly after nocodazole washout. 
2.4.7 KAT2A-mediated acetylation of TUBA increases microtubule reassembly 
Since defective autophagy resulted in KAT2A accumulation and KAT2A induced TUBA 
acetylation, a marker of microtubule stabilization, we assessed whether KAT2A regulates 
microtubule reassembly. To this end, we transfected HASMCs with adenovirus encoding Flag-
KAT2A or GFP for 48 h and then treated the cells with nocodazole for 30 min to depolymerize 
microtubules. Tubulin acetylation was assessed by western blot and immunofluorescence 
microscopy after removal of nocodazole. The results showed that autophagy deficiency results in 
KAT2A accumulation (Fig. 2.10A and B), overexpression of KAT2A in HASMCs promoted the 
recovery of acetylated TUBA protein levels following nocodazole washout (Fig. 2.10A and B). 
Consistently, immunofluorescence analysis indicated a substantial amount of acetylated TUBA 
in HASMCs overexpressed KAT2A (Fig. 2.10C and D). On the contrary, KAT2A silencing 
reduced acetylated TUBA protein levels under basal conditions and delayed the recovery of 
acetylated TUBA protein levels after nocodazole washout (Fig. 2.10E and F). Collectively, 
KAT2A-induced TUBA acetylation increases microtubule reassembly under autophagy-deficient 
conditions. 
2.4.8 Autophagy controls the directional migration of VSMCs 
As autophagy dynamically modulates microtubule stability, which is an essential 
requirement for directional cell migration (40), we examined the role of the autophagy-KAT2A-
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TUBA acetylation axis in cell polarization and subsequent cell migration. We first examined the 
effect of autophagy inhibition on cell polarity using the scratch wound healing assay. We found 
that inhibition of autophagy by ATG7 siRNA interfered with microtubule-organizing center 
(MTOC) reorientation in the leading cells (Fig. 2.11A and B), as evidenced by larger angles (θ) 
in ATG7 siRNA-treated cells relative to those of control siRNA-treated cells. In addition, in 
control siRNA-treated HASMCs, the first two layers of leading cells were clearly polarized 
toward the leading edge, as shown via staining of the stabilized microtubules with acetylated-
TUBA antibody. Inhibition of autophagy by ATG7 silencing, however, dramatically increased 
the level of stable microtubules in the first two layers of leading cells and resulted in a loss of 
orientation toward the leading edge in these cells (Fig. 2.11C).  
Finally, we tested the effect of autophagy on HASMC migration. In the scratch wound 
healing assay, control siRNA-treated cells migrated into the wound area and organized a dense 
cellular network, resulting in nearly complete wound recovery after 48 h, while siRNA silencing 
of either ATG7 or BECN1 significantly inhibited cell migration into the wound area (Fig. 2.11D 
and E). The transwell assay also showed that transfection of HASMCs with ATG7 or BECN1 
siRNA drastically reduced cell migration through the filter membrane (Fig. 2.11F and G). 
Conversely, adenoviral overexpression of ATG5 or ATG7 significantly promoted cell migration 
into the wound areas (Fig. 2.11H and I) and significantly increased the numbers of HASMCs 
that migrated through the filter membrane (Fig. 2.11J and K). These data suggest that autophagy 
is required to establish front-rear polarity and proper cell migration, presumably through the 
regulation of microtubule acetylation and stabilization. 
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2.4.9 KAT2A is required for autophagy regulation of VSMC migration 
            To determine whether KAT2A-acetylated TUBA mediated autophagy-regulated cell 
migration, we first examined whether KAT2A regulates cell migration. We transfected HASMCs 
with control or KAT2A siRNA and found that KAT2A silencing (Fig. 2.12A) promoted cell 
migration into the wound areas in the scratch wound healing assay (Fig. 2.12B, C). Conversely, 
adenoviral overexpression of KAT2A inhibited cell migration through the membrane in the 
transwell assay (Fig. 2.12D-F). We then co-transfected HASMCs with ATG7 and KAT2A siRNA 
and examined cell migration. Transfection of ATG7 siRNA reduced ATG7 protein expression 
and concomitantly increased protein levels of KAT2A and acetylated TUBA. Administration of 
KAT2A siRNA prevented ATG7 siRNA-enhanced acetylation of TUBA (Fig. 2.12G). Notably, 
ATG7 silencing inhibited VSMCs migration into the wound area, while KAT2A silencing 
promoted this VSMC migration. The observed inhibition of VSMCs migration attained by ATG7 
silencing was attenuated by silencing of KAT2A (Fig. 2.12H and I).  
            To establish links between KAT2A, TUBA acetylation, and VSMCs migration, we co-
transfected HASMCs with KAT2A adenovirus and WT TUBA plasmid or with KAT2A 
adenovirus and a dominant negative Lys40 acetylation-defective TUBA plasmid (TUBAK40R) 
(38). In the cells transfected with WT TUBA, overexpression of KAT2A reduced the numbers of 
cells that migrated through the membrane compared with overexpression of GFP. Transfection 
of cells with the TUBAK40R mutant, however, significantly prevented KAT2A-induced reduction 
in VSMCs migration (Fig. 2.12J, K). Together, these findings indicate that KAT2A-mediated 
acetylation of TUBA is required for defective autophagy inhibition of VSMC migration. 
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2.5 Discussion 
            In this study, we showed that selective autophagic degradation of histone 
acetyltransferase KAT2A controls cell migration by regulating microtubule stability. KAT2A 
binds directly to the autophagic effector protein LC3 via an LIR motif, which mediates 
autophagic degradation of KAT2A. Suppression of autophagy resulted in KAT2A accumulation, 
and KAT2A-induced TUBA acetylation increased microtubule stability, leading to an inhibition 
of cell migration. Together, our results demonstrate that autophagy controls microtubule stability 
by regulating KAT2A protein expression.  
            Although autophagy has been considered a non-specific degradation process, recent 
studies demonstrated that autophagy is also critical for the degradation of specific cargo, such as 
organelles and proteins (13,41,42). In agreement with these findings, we observed that inhibition 
of autophagy led to an increase in KAT2A protein levels but had no effect on KAT2A mRNA 
expression, whereas activation of autophagy reduced KAT2A protein expression and 
administration of a proteasome inhibitor had no effect on KAT2A protein expression. In 
addition, KAT2A contains an LIR motif, which mediates the association between KAT2A and 
LC3, recruiting KAT2A to autophagosomes. Deletion of the LIR motif prevented the 
degradation of KAT2A by starvation-induced autophagy. These data indicate that KAT2A is 
selectively degraded through the autophagy-lysosomal pathway and that the interaction between 
KAT2A and LC3 via the LIR motif is required for degradation of KAT2A by autophagy.     
             SQSTM1 has been proposed to contribute to selective autophagy of protein aggregates 
and depolarized mitochondria (43). Thus, we investigated whether SQSTM1 is required for 
KAT2A degradation by autophagy. Although LC3 bound to SQSTM1 and KAT2A separately, 
KAT2A was not associated with SQSTM1. Importantly, gene silencing of SQSTM1 did not 
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disrupt the association between KAT2A and LC3, indicating that SQSTM1 is not involved in the 
interaction between KAT2A and LC3 and that direct binding between KAT2A and LC3 
mediates autophagic degradation of KAT2A.  
             Tubulin acetylation was first described 20 years ago, but little is known about the 
enzymes that catalyze this reaction. Recent evidence suggests that Atat1/atat-2 may function as 
the major TUBA acetyltransferase in C. elegans (44) and mice (45). In C. elegans, loss of atat-2 
leads to disruption of microtubule structural integrity and axonal morphologic defects in touch 
receptor neurons (46). In mice, ATAT1 is highly expressed in testis, kidney, and brain (45), the 
loss of ATAT1 results in brain abnormalities (45) and abnormal sperm morphology and motility 
(47). Because neither activation nor suppression of autophagy alters ATAT1 expression, it is 
unlikely that autophagy via ATAT1 regulates TUBA acetylation in our system.  
             In the current study, we demonstrated that KAT2A is the enzyme that mediates 
acetylation of TUBA in VSMCs, The following lines of evidence support this conclusion: co-
immunoprecipitation indicated that KAT2A physically associates with TUBA, 
immunofluorescence analysis revealed that endogenous KAT2A colocalized with acetylated 
TUBA, and an in vitro tubulin acetylation assay showed that full-length recombinant KAT2A 
induces acetylation of TUBA. Furthermore, KAT2A silencing decreased TUBA acetylation, 
while overexpression of KAT2A increased TUBA acetylation. Importantly, overexpression of 
KAT2A increased acetylation of WT-TUBA but failed to induce acetylation of TUBAK40R 
mutant, in which Lys40 was substituted with arginine (38). Thus, KAT2A represents a newly 
described acetyltransferase that targets TUBA. KAT2A, which is first identified as a global 
coactivator, and transcription-related histone acetyl transferase (48), has been reported to be 
involved in a broad range of cellular processes including gene transcription, differentiation, DNA 
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repair, nucleosome assembly, and cell cycle regulation (49). Although our results strongly 
indicate suggests that KAT2A directly acetylates TUBA, we cannot exclude that it can indirectly 
regulates TUBA acetylation via other molecules. Deacetylation of TUBA is mediated by both 
HDAC6 and SIRT2 (7,8); however, the increased acetylation of TUBA in autophagy-deficient 
conditions may not be mediated by either of these deacetylases because neither activation nor 
suppression of autophagy alters the expression of HDAC6 or SIRT2.  
            The extent and duration of autophagy are crucial for cell heath, and acute and chronic 
manipulations of autophagy have led to, in several instances, controversial conclusion. Our 
results are consistent with the findings that induction of autophagy is coupled to reduction of 
H4K16ac (28), and α-lipoic acid inhibits cellular autophagic flux and promotes the rapid 
hyperacetylation of TUBA (50). However, other groups also showed that nutritional stress 
triggers hyperacetylation of tubulin in HeLa cells by an unidentified mechanism (51), and 
voluntary exercise increases acetylated tubulin levels, associated with activation of autophagy in 
mutated CRYABR120G (CryABR120G) transgenic mouse hearts (52). 
            Accumulating evidence suggests that microtubules regulate autophagosome formation 
and transportation in axon (53,54). Whether autophagy in turn modulates microtubule stability in 
VSMCs is not known. In the present study we found that suppression of autophagy resulted in 
KAT2A accumulation, and KAT2A-induced TUBA acetylation increased microtubule stability, 
leading to an inhibition of cell migration. This finding is consistent with the report that inhibition 
of the HDAC6 by siRNA or tributyrin increased tubulin acetylation and inhibited endothelial cell 
migration (55). However the role of autophagy on microtubule stability seems to be different in 
different cell types, because a recent study showed that activation of autophagy increases 
microtubule stability through the degradation of STMN2 (stathmin 2), a microtubule 
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destabilization protein, and promotes axon regeneration after spinal cord injury (56). STMN2 is a 
neuron-specific, membrane-associated protein that is highly concentrated in growth cones of 
developing neurons. Thus, further investigations are warranted to determine the role of 
autophagy on microtubule stability in different cell types.   
            Microtubule stability plays important roles in autophagy. Treatment of cells with 
nocodazole leads to complete depolymerization of both labile and stable microtubules and fully 
inhibits autophagic flux. Autophagosome formation is also inhibited by treatment with taxol, a 
drug that stabilizes microtubules and interferes with the dynamic turnover of the microtubule 
network (57). It is now clear that microtubules are involved in autophagosome formation (58). 
First, microtubules interact with ATG proteins, including LC3, ULK1, BECN1, ATG5, and 
ATG12, supporting the assembly of pre-autophagosomal structure (59). Second, microtubules 
regulate two major complexes (MTORC1 and PtdIns3K complex) (59) involved in the initiation 
of autophagy. In VSMCs, activation of autophagy results in destabilization of microtubules, 
which may inhibit the interaction between microtubules and ATG proteins and prevent the 
formation of initiation complexes, MTORC1 and PtdIns3K complex, therefore tuning down 
autophagy. 
            The role of TUBA acetylation on microtubule stability has been controversial. Early 
studies indicated that TUBA acetylation had no effect on microtubule polymerization (60); 
however, more recent studies reported that increased acetylation of TUBA by HDAC6 inhibition 
increases microtubule stability and inhibits cell motility (61,62). Since HDAC6 may regulate 
many other proteins in addition to TUBA, it has been difficult to determine whether these results 
are direct effects of HDAC6-mediated deacetylation of microtubules or indirect effects via other 
molecules. In our study, we found that KAT2A induced TUBA acetylation and dose-dependently 
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increased microtubule polymerization. Overexpression of KAT2A protected microtubules from 
nocodazole-induced depolymerization, supporting the notion that acetylation of TUBA stabilizes 
microtubules. We also observed that KAT2A silencing increased cell migration into the wound 
area in a scratch wound healing assay. Overexpression of KAT2A inhibited cell migration in 
cells transfected with WT TUBA, but transfection of cells with the TUBAK40R mutant 
significantly attenuated this KAT2A-induced inhibition of VSMC migration, suggesting that 
KAT2A-mediated acetylation of TUBA inhibits cell migration. However, the role of stabilized 
microtubules in migration is greatly understudied. It has been reported that reduced TUBA 
acetylation impairs migration in neuronal cell lines (5,63), and in breast cancer cells (64). 
Conflicting reports have suggested that HDAC inhibitors, specifically targeting HDAC6’s 
tubulin deacetylase activity, reduces cancer migration by increasing TUBA acetylation in 
estrogen receptor-positive breast cancer (65), in addition, enhanced acetylated TUBA decreased 
cell motility in a human non-small cell lung carcinoma cell line (H1299) and NIH 3T3 
fibroblasts (8,66). Moreover, hyperacetylation of tubulin suppressed cell migration in endothelial 
cells (55). Our results suggest that acetylation of TUBA increases microtubule stability and 
inhibits cell motility in VSMCs. 
            Recent studies have clearly demonstrated that autophagy has a greater variety of 
physiological and pathophysiological roles, including starvation adaptation, intracellular protein 
and organelle clearance, elimination of microorganisms, and antigen presentation (42,67,68). We 
further demonstrated that autophagy regulates microtubule dynamics and cell motility through 
modulating TUBA acetylation. The role of autophagy in regulation of VSMC migration remains 
a subject of debate in the literature. Consistent with our findings, both PDGF-BB and 1-
palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC) induce autophagy and 
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concomitantly promote the loss of contractile gene expression and increase cell proliferation and 
migration (69,70). By contrast, administration of the autophagy inducer rapamycin inhibits cell 
proliferation and prevents restenosis after angioplasty (71,72). These effects of rapamycin are 
unlikely due to its activation of autophagy (70). Rather, the drugs appear to prevent proliferation 
and migration by inhibiting RPS6KB1/S6K1 (ribosomal protein S6 kinase, polypeptide 1) 
(73,74) and regulating the expression of key cell cycle protein CDKN1B/p27Kip1 (75). 
Intriguingly, rapamycin promotes Schwann cell migration via unidentified mechanisms (76). 
Another study demonstrated that VSMC-specific deletion of ATG7 accelerates senescence and 
promotes neointimal formation and atherogenesis (18). One explanation for this discrepancy is 
that autophagy can also occur in the absence of some key autophagy proteins, such as ATG5 and 
ATG7, through unconventional biogenesis of canonical autophagosomes (32). In addition, ATG7 
has been reported to regulate TRP53/p53-dependent cell cycle and cell death pathways 
independent of autophagy during metabolic stress (77). Thus, further investigation is necessary 
to determine the role of autophagy in regulating VSMC migration. A mouse with VSMC-specific 
deletion of ULK1, a protein essential for regulating both ATG5/ATG7-dependent and 
ATG5/ATG7-independent autophagy (32), may be useful for these investigations. 
            In conclusion, KAT2A is the acetyltransferase responsible for acetylation of TUBA and 
is selectively degraded by the autophagy-lysosomal pathway. Stabilization of microtubules by 
KAT2A-mediated acetylation of TUBA is an important mechanism by which defective 
autophagy inhibits VSMC migration. Our findings suggest that autophagy suppression in 
VSMCs may be an important therapeutic target for atherosclerosis and intimal hyperplasia. 
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Figure 2.1 Manipulation of autophagy in mouse embryonic fibroblasts (MEFs) and human aortic smooth 
muscle cells (HASMCs). 
(A) Protein levels of ATG5, ATG7, SQSTM1, LC3, and ACTB/β-actin in wild-type (WT), atg5
-/-
, and 
atg7
-/-
 MEFs were analyzed by western blot. n=3, *P<0.05, ***P<0.001 vs. WT. (B) WT MEFs were 
starved with Hanks balanced salt solution (HBSS) for 3 h, and protein levels of SQSTM1, LC3, and 
ACTB/β-actin were analyzed by western blot. n=3, **P<0.01 vs. Con. (C) HASMCs were transfected 
with control siRNA (C-siRNA), ATG5 siRNA, or ATG7 siRNA for 48 h. Protein levels of ATG5, ATG7, 
SQSTM1, LC3, and ACTB/β-actin were measured by western blot. n=3, **P<0.01, ***P<0.001 vs. C-
siRNA. (D) HASMCs were starved with HBSS for 3 h, and protein levels of SQSTM1, LC3, and 
ACTB/β-actin were analyzed by western blotting. n=3, *P<0.05, **P<0.01 vs. Con. (E) HASMCs were 
transfected with control siRNA (C-siRNA) or BECN1 siRNA, and protein levels of SQSTM1, LC3, and 
ACTB/β-actin were detected by western blotting. n=3, ***P<0.001 vs. C-siRNA. (F) Western blot 
analysis of ULK1, SQSTM1, LC3, and ACTB/β-actin in HASMCs transfected with control siRNA (C-
siRNA) or ULK1 siRNA (ULK1-si). n=3, **P<0.01, ***P<0.001 vs. C-siRNA. 
 
63 
 
Figure 2.2 Autophagy regulates TUBA acetylation. 
 (A) Western blot analysis of protein acetylation in wild-type (WT), atg5-/-, and atg7-/- mouse embryonic 
fibroblasts (MEFs). n=5, *P<0.05 vs. WT. (B) WT MEFs were starved with Hank's balanced salt solution 
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(HBSS) for 3 h, and acetylated proteins were analyzed by western blotting. n=5, *P<0.05 vs. control 
(con). (C) Human aortic smooth muscle cells (HASMCs) were transfected with control siRNA (C-
siRNA) or siRNA targeting ATG5 (ATG5-si) or ATG7 (ATG7-si) for 48 h. Protein acetylation was 
measured by western blotting. n=5, *P<0.05 vs. C-siRNA. (D) HASMCs were starved with HBSS for 3 
h. Protein acetylation was analyzed by western blot. n=5, *P<0.05 vs. Con (E) Western blot analysis of 
acetylation of TUBA (Ac-TUBA) in WT, atg5-/-, and atg7-/- MEFs. n=5, *P<0.05 vs. WT. (F) Western 
blot analysis of Ac-TUBA in MEFs subjected to starvation. n=5, *P<0.05 vs. Con. (G) Levels of Ac-
TUBA were determined by western blot in HASMCs transfected with C-siRNA, ATG5 siRNA, or ATG7 
siRNA. n=5, *P<0.05 vs. C-siRNA. (H) Western blot analysis of Ac-TUBA in HASMCs subjected to 
starvation. n=5, *P<0.05 vs. Con. (I) Western blots detected the indicated proteins in HASMCs 
transfected with C-siRNA or BECN1 siRNA (BECN1-si). n=5, *P<0.05 vs. C-siRNA. (J) Western blot 
analysis of Ac-TUBA in HASMCs transfected with C-siRNA or ULK1 siRNA (ULK1-si). n=5, *P<0.05 
vs. C-siRNA. 
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Figure 2.3 Autophagy inhibition increases KAT2A protein levels. 
 (A) HASMCs were transfected with control siRNA (C-siRNA) or BECN1 siRNA for 48 h. Protein levels 
of KAT2A/GCN5, LC3, and BECN1 were determined by western blotting. (B) Levels of KAT2A, 
ATAT1, HDAC6, KAT8/hMOF, EP300, SIRT1, and SIRT2 in HASMC lysates transfected with control 
siRNA (C-siRNA) or ULK1 siRNA were detected by western blotting. (C and D) HASMCs were starved 
with HBSS for 3 h. (C) Protein levels of KAT2A, ATAT1, KAT8, EP300, SIRT1, and SIRT2 were 
analyzed by western blot. (D) Protein levels of HDAC4, HDAC5, HDAC6, HDAC7, and HDAC9 were 
analyzed by western blot. (E-H) HASMCs were transfected with adenovirus encoding GFP (Ad-GFP), 
ATG5 (Ad-ATG5), or ATG7 (Ad-ATG7) for 48 h. Protein levels of ATG5, ATG7, SQSTM1, and ACTB/β-
actin were analyzed by western blot and densitometry. n=3, **P<0.01, ***P<0.001 vs. Ad-GFP. 
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Figure 2.4 Autophagy inhibition increases KAT2A protein levels. 
(A-C) HASMCs were transfected with control siRNA (C-siRNA), ATG5 siRNA (ATG5-si), or ATG7 
siRNA (ATG7-si) for 48 h. Protein levels of KAT2A and LC3-I or LC3-II were analyzed by western 
blotting and densitometry. n=3, *P<0.05 vs. C-siRNA. (D) KAT2A mRNA was measured by quantitative 
real-time PCR. (E-G) Western blot and densitometry analysis of KAT2A and LC3-I or LC3-II protein 
levels in WT, atg5-/-, and atg7-/- MEFs. n=3, **P<0.01 vs. WT, ***P<0.001 vs. WT. (H) Expression of 
KAT2A mRNA in WT, atg5-/-, and atg7-/- MEFs. (I-K) HASMCs were transfected with Ad-GFP, Ad-
ATG5, or Ad-ATG7 for 48 h. Protein levels of KAT2A and LC3-I or LC3-II were evaluated by western 
blotting and densitometry. n=3, *P<0.05, **P<0.01, ***P<0.001 vs. ad-GFP. (L) WT and atg5-/- MEFs 
were starved with HBSS for the indicated time points. Protein levels of KAT2A, LC3-I or LC3-II, and 
ATG5 were analyzed by western blotting. (M) The LC3-II to LC3-I ratio was analyzed by densitometry. 
n=3, **P<0.01 vs. control. (N) KAT2A degradation was analyzed by densitometry. n=3, *P<0.05 vs. 
atg5-/- MEFs; #P<0.05 vs. atg5-/- 0 h. (O) HeLa cells were transfected with plasmid encoding GFP or Flag-
KAT2A for 48 h and then starved with HBSS for the indicated time points. Expression of Flag-KAT2A 
was determined by western blotting. (P) HASMCs were treated with chloroquine (CQ, 10 µM) or 
lactacystin (Lacta, 5 µM) for 24 h. Levels of KAT2A, SQSTM1, LC3-I or LC3-II and RUNX2 were 
analyzed by western blotting.  
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Figure 2.5 KAT2A is degraded through the autophagic-lysosomal pathway. 
(A) HASMCs were transfected with an adenovirus encoding GFP-LC3 for 24 h and then treated with 
chloroquine for 16 h. KAT2A was stained by immunocytochemistry, and the co-localization (yellow) of 
KAT2A (red) and GFP-LC3 puncta was evaluated by immunofluorescence microscopy. Scale bar, 20 µm. 
(B) HeLa cells were transfected with EGFP or EGFP-LC3 plasmid for 24 h. The interaction between 
69 
KAT2A and LC3B was determined by immunoprecipitation (IP) of KAT2A and subsequent western 
blotting (WB) with GFP. (C) Recombinant full-length KAT2A was incubated with GST- or GST-LC3-
immobilized beads and then subjected to SDS-PAGE. KAT2A was detected with KAT2A antibody. 
Coomassie staining was used to visualize GST and GST-LC3 proteins. (D) HeLa cells were transfected 
with plasmid encoding Myc-LC3 for 48 h, and the interaction between LC3 and SQSTM1 was 
determined by IP and WB as indicated. (E) HeLa cells were transfected with plasmid encoding Flag-
KAT2A for 48 h, and the interaction between KAT2A and SQSTM1 was determined by IP and WB as 
indicated. (F) HeLa cells were transfected with the indicated KAT2A constructs for 24 h. Cell lysates 
were immunoprecipitated using IgG or KAT2A antibody, and LC3B antibody was used for WB. (G) 
HeLa cells were transfected with plasmids encoding WT and KAT2AY734A, L737A mutant for 24 h. Cells 
were lysed and immunoprecipitated using IgG or KAT2A antibody. The immunoprecipitated proteins 
were detected by western blotting with LC3B antibody. (H and I) HeLa cells were transfected with WT or 
KAT2AY734A, L737A mutant for 48 h and then starved with incubation in HBSS for 3 h to activate 
autophagy. KAT2A protein levels were analyzed by WB and densitometry. n=3, ***P<0.001 vs. 
KAT2A-HA/Medium; ###P<0.001 vs. KAT2A-HA/HBSS. 
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Figure 2.6 SQSTM1 is not involved in the interaction between KAT2A and LC3. 
HEK293 cells were transfected with KAT2A-GFP or KAT2AΔ3-GFP plasmid for 48 h, and the 
interaction between KAT2A and LC3 was analyzed by immunoprecipitation (IP) and western blot (WB). 
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Figure 2.7 Analysis of LC3 binding region (LIR) in KAT2A and KAT2A truncation variants. 
(A) Typical LC3 binding region sequences (W/F/YxxL/I/V) in known autophagy substrates are shown. 
(B) Sequence alignment of KAT2A with candidate LIR domains depicted in red. (C) Illustration of the 
different KAT2A truncation variants. 
 
 
 
 
 
 
 
72 
 
Figure 2.8 KAT2A acetylates TUBA. 
 (A) The interaction of KAT2A and TUBA in atg5-/- MEFs was determined by immunoprecipitation and 
western blotting. (B) Purified porcine brain tubulin protein was incubated with recombinant KAT2A-
catalytic domain protein in acetylation buffer at 37°C for 1 h. The acetylation of TUBA (Ac-tubulin) was 
assessed by western blotting. n=3, ***P<0.001. (C-E) HASMCs were transfected with control siRNA (C-
siRNA) or KAT2A siRNA (KAT2A-si). Expression of KAT2A and acetylation of TUBA were examined 
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by western blot and densitometry. n=3, **P<0.01. (F-H) HASMCs were transfected with control siRNA 
(C-siRNA) or KAT2A siRNA (KAT2A-si). Acetylation of TUBA was analyzed by immunofluorescence. 
Scale bar, 50 µm. n= 3, ***P<0.001. (I and J) HEK 293 cells were transfected with a plasmid encoding 
Flag-KAT2A for 48 h. Acetylation of TUBA was assayed by western blotting and densitometry. n=3, 
*P<0.01. (K) HEK293 cells were co-transfected with plasmid encoding LacZ, KAT2A, EGFP-WT-
TUBA, or EGFP-TUBAK40R for 48 h. Acetylation of TUBA was examined by western blotting.  
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Figure 2.9 Autophagy deficiency increases microtubule stability. 
(A) HASMCs were transfected with control siRNA (C-siRNA) or ATG7 siRNA (ATG7-si) for 48 h. 
TUBA and Ac-TUBA was stained by immunocytochemistry. Scale bar, 20 µm. (B) Quantitative analysis 
of TUBA and Ac-TUBA intensity. n=3, ***P<0.001. (C) HASMCs transfected with C-siRNA or ATG7-
si were incubated at 0ºC for 0, 5, 10, 15, or 30 min. The morphology of microtubules was examined using 
immunostaining of TUBA and confocal microscope. Scale bar, 20 µm. (D) Quantitative analysis of 
microtubule intensity. n=25/group, ***P<0.001. (E) WT and atg5
-/-
 MEFs were treated with nocodazole 
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for 30 min, and then the drug was washed out to allow the microtubules to repolymerize for the indicated 
times. Acetylation of TUBA (Ac-TUBA) in cell lysates were analyzed by western blot. St, steady-state 
situation without nocodazole treatment. (F) Densitometry analysis of acetylation of TUBA levels. n=3, 
*P<0.05, **P<0.01, ***P<0.001.  
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Figure 2.10 KAT2A-mediated acetylation of TUBA increases microtubule reassembly. 
(A) HASMCs were transfected with adenovirus encoding GFP and KAT2A. Cells were treated with 
nocodazole for 30 min, and then the drug was washed out to allow the microtubules to repolymerize for 
the indicated times. Cell lysates were analyzed by western blot. St, steady-state situation without 
nocodazole treatment. (B) Densitometry analysis of acetylated TUBA level. n=3, *P<0.05. (C) HASMCs 
were transfected with adenovirus encoding β-gal or KAT2A for 48 h, and acetylation of TUBA was 
measured using immunofluorescence. Scale bar, 20 µm. (D) Quantitative analysis of TUBA and Ac-
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TUBA intensity. n=3, ***P<0.001. (E) HASMCs were transfected with control siRNA (C-siRNA) or 
KAT2A-siRNA (KAT2A-si), and cells were subjected to the nocodazole-washout assay as described. (F) 
Densitometry analysis of acetylated TUBA levels. n=3, *P<0.05. 
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Figure 2.11 Autophagy is required for polarization and directional migration of VSMCs in vitro. 
(A) Representative images of HASMCs stained with TUBG antibody in cells subjected to a scratch 
wound assay. The cells were treated with control siRNA or ATG7 siRNA for 48 h, and the images were 
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captured 6 h after the scratch. Scale bar, 20 µm. The cell polarization was assessed by the angles (θ) 
between the lines of TUBG and the scratched line at the center of each nucleus as a marker for 
microtubule-organizing center (MTOC) reorientation. (B) Quantitation of the angles (θ). n=100, *P<0.01 
vs. C-siRNA. (C) Images of HASMC stained with TUBA (green) and Ac-TUBA (red) antibodies in cells 
subjected to the scratch wound assay. Nuclei were stained with DAPI (blue). The cells were transfected 
with control siRNA or ATG7 siRNA. Scale bar, 50 µm. (D-G) HASMCs were transfected with control 
siRNA (C-siRNA), ATG7 siRNA (ATG7-si), or BECN1 siRNA (BECN1-si) for 48 h. (D) Representative 
images of HASMC migration in the scratch wound assay. Scale bar, 1 mm.  (E) Migration distances of 
HASMCs. n=4, **P<0.01 vs. C-siRNA. (F) Cell migration was determined by transwell migration assays. 
Scale bar, 1 mm. (G) Migrated cells were quantified. n=5, ***P<0.001 vs. C-siRNA. (H-K) HASMCs 
were transfected with adenovirus encoding GFP, ATG5, or ATG7 for 48 h. (H) Representative images of 
HASMC migration in the scratch wound assay. Scale bar, 1 mm. (I) Migration distances of HASMCs. 
n=4, *P<0.05 vs. C-siRNA. (J) Cell migration was determined by transwell migration assays. Scale bar, 1 
mm. (K) Migrated cells were quantified. n=4, *P<0.05 vs. C-siRNA. 
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Figure 2.12 KAT2A inhibits VSMC migration by acetylating TUBA. 
(A-C) HASMCs were transfected with control siRNA (C-siRNA) or KAT2A-siRNA (KAT2A-si) for 48 h. 
(A) KAT2A levels were analyzed by western blot. (B) Representative images of HASMC migration in the 
scratch wound assay. Scale bar, 1 mm. (C) Migration distances of HASMCs. n=4, * P<0.05 vs. C-siRNA. 
(D-F) HASMCs were transfected with Ad-GFP or Ad-KAT2A for 48 h. (D) Levels of KAT2A were 
analyzed by western blotting. (E) Cell migration was determined by transwell migration assays. Scale bar, 
1 mm. (F) Migrated cells were quantified. n=5, *P<0.05 vs. C-siRNA. (G-I) HASMCs were transfected 
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with control siRNA (C-siRNA), ATG7 siRNA, or ATG7 and KAT2A siRNA for 48 h. (G) Levels of 
acetylated TUBA (Ac-TUBA), KAT2A, and ATG7 in cell lysates were measured by western blotting. (H) 
Representative images of HASMC migration in the scratch wound assay. Scale bar, 1 mm. (I) Migration 
distances of HASMCs. n=3, *P<0.05 vs. C-siRNA. #P<0.05 vs. ATG7-siRNA. (J) HASMCs were co-
transfected with Ad-GFP/WT TUBA, Ad-KAT2A/WT TUBA, or Ad-KAT2A/TUBAK40R mutant for 48 h. 
Cell migration was determined by transwell migration assays. Scale bar, 1 mm. (K) Migrated cells were 
quantified. n=5, ***P<0.001 vs. Ad-GFP/WT TUBA; ###P<0.001 vs. Ad-KAT2A/WT TUBA.  
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3.1 Abstract 
           BRD4 is a member of the BET family of epigenetic regulators. Inhibition of BRD4 by the 
selective bromodomain inhibitor JQ1, alleviates thoracic aortic constriction-induced cardiac 
hypertrophy and heart failure. However, whether BRD4 inhibition by JQ1 has therapeutic effect 
on diabetic cardiomyopathy, a major cause of heart failure in patients with Type 2 diabetes, 
remains unknown. Here, we discover a novel link between BRD4 and PINK1/Parkin-mediated 
mitophagy during diabetic cardiomyopathy. Upregulation of BRD4 in diabetic mouse hearts 
inhibits PINK1/Parkin-mediated mitophagy, resulting in accumulation of damaged mitochondria 
and subsequent impairment of cardiac structure and function. BRD4 inhibition by JQ1 improves 
mitochondrial function, and repairs the cardiac structure and function of the diabetic heart. These 
effects depended on rewiring of the BRD4-driven transcription and repression of PINK1. 
Deletion of Pink1 suppresses mitophagy, exacerbates cardiomyopathy, and abrogates the 
therapeutic effect of JQ1 on diabetic cardiomyopathy. Our results illustrate a valid therapeutic 
strategy for treating diabetic cardiomyopathy by inhibition of BRD4. 
3.2 Introduction 
           Diabetes affects 30.3 million people in the United States (9.4% of the population) and 
more than 347 million people worldwide. Type 2 diabetes is the most common form of diabetes, 
affecting 90% to 95% of all patients with diabetes. Diabetic cardiomyopathy is a major cause of 
heart failure in patients with Type 2 diabetes (1). Although multiple factors may collectively 
contribute to the development of diabetic cardiomyopathy, the exact mechanisms underlying this 
pathological process are poorly understood. 
           Autophagy is an intracellular catabolic pathway by which long-lived proteins and 
organelles are delivered to lysosomes for degradation. Autophagy is controlled by autophagy-
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related genes (Atgs) and is critical for cardiac homeostasis (2). Increasing evidence demonstrates 
that autophagy is inhibited in the cardiac tissue of Type 1 (3,4) and Type 2 (5-8) diabetic mouse 
models and contributes to the development of diabetic cardiomyopathy. Mitophagy is a specific 
type of autophagy that specifically degrades impaired mitochondria (9). In addition to core 
autophagic machinery components, mitophagy exploits a variety of molecules to identify and 
eliminate damaged or superfluous mitochondria (10). PTEN-induced putative kinase protein 1 
(PINK1) and the Parkin pathway, which activates mitophagy in an ubiquitination-dependent 
manner, is the most well studied mitophagy pathway (11). Bromodomain-containing protein 4 
(BRD4) belongs to bromodomain and extra-terminal domain (BET) family of proteins. It binds 
to acetylated histones and transcription factors through its bromodomains and recruits 
transcriptional regulators (12). JQ1, one of the BET bromodomain inhibitors, has therapeutic 
effect on different diseases (13-15). In the cardiovascular system, administration of JQ1 
attenuates pulmonary arterial hypertension (16), angiotensin II-induced hypertension (17), 
abdominal aortic aneurysm (18), transverse aortic constriction-induced cardiac hypertrophy, and 
heart failure (19,20) in animal models. Furthermore, a recent study showed that administration of 
JQ1 prevents high glucose-induced hypertrophy and fibrosis‑associated gene expression in H9c2 
cardiomyoblast cells (21). Collectively, these data suggest the involvement of BET family 
proteins in cardiovascular diseases. However, the role of BRD4 in the development of 
cardiomyopathy in Type 2 diabetes remains unknown.  
           Here we report that cardiac BRD4 is upregulated in high-fat diet (HFD)-induced diabetic 
cardiomyopathy and inhibits PINK1/Parkin-mediated mitophagy, which impairs mitochondria 
and cardiac structure and function. BRD4 inhibition with JQ1 restores PINK1/Parkin-mediated 
mitophagy and prevents HFD-induced diabetic cardiomyopathy. 
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3.3 Materials and methods 
3.3.1 Mouse models and JQ1 treatment 
Wild-type (WT, C57BL/6J, stock number 000664) and Pink1-/- mice (B6.129S4 
Pink1tm1Shn/J, stock number 017946) were purchased from Jackson Laboratories. 2-month-old 
male mice were subjected to ND (normal diet) or HFD (Research Diets D12492) consumption 
for 6 months. To determine if PINK1 mediates the therapeutic effect of JQ1, we divided male 
WT and Pink1-/- mice into four groups: ND + DMSO, ND + JQ1, HFD + DMSO, and HFD + 
JQ1. JQ1 (MedChem Express) and vehicle preparation were described previously (19). In the 
last month of ND or HFD treatment, WT and Pink1-/- mice were treated intraperitoneally with 
DMSO or JQ1 (10 mg/kg/day). Body weights were recorded daily. All animal protocols were 
approved by the Institutional Animal Care and Use Committee of Georgia State University. 
3.3.2 Comprehensive metabolic monitoring 
Mice were analyzed for whole energy expenditure, oxygen consumption, carbon dioxide 
production, and respiratory exchange ratio (vCO2/vO2) using calorimetric systems 
(PhenoMaster, TSE Systems, Bad Homburg, Germany). Mice were individually housed and 
acclimated to chambers for 3 days before experimental measurements and allowed free access to 
food and water.  
3.3.3 Echocardiography 
Echocardiography was performed using a Vevo 3100 High-Resolution Micro-Ultrasound 
System (FUJIFILM Visual Sonics Inc., Toronto, Canada) as previously described (22). M-mode 
tracings were used to measure LV wall thickness, LV end-systolic diameter, and LV end-
diastolic diameter. FS and EF were calculated from LV dimensions in the 2D short-axis view. 
Diastolic function was measured using tissue Doppler imaging and color Doppler imaging. 
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Tissue Doppler was used to measure the peak myocardial relaxation velocity at the mitral valve 
annulus during early diastole and early filling deceleration time. Color Doppler was used to 
obtain a sharper signal from the early ventricular filling peak velocity (E wave) and late filling 
velocity (A wave). All examinations were analyzed using Vevo Lab 2.1.0 software. 
3.3.4 Cell culture and treatment 
Mouse neonatal cardiomyocytes were isolated from C57BL/6J mice using an adapted 
protocol from the Pierce Primary Cardiomyocyte Isolation Kit (#88281, Thermo Fisher 
Scientific). Briefly, neonatal mouse hearts were freshly dissected and incubated with 
Cardiomyocyte Isolation Enzyme 1 and Enzyme 2 at 37°C for 30-35 minutes. Then, the tissue 
was disrupted in complete DMEM with cardiomyocyte growth supplement. Total cell yield was 
determined using a TC20™ Automated Cell Counter (Bio-Rad Laboratories) and cell viability 
was determined using a trypan blue exclusion assay. Isolated neonatal cardiomyocytes were then 
plated on dishes and incubated at 37°C in 5% CO2 for further experiments. 
Palmitate (PA) was prepared as a PA-BSA conjugate. Mouse neonatal cardiomyocytes 
were treated with 200 µM of PA for 48 hours or 500 nM of JQ1 for 24 hours. Control groups 
were treated with bovine serum albumin (BSA) or DMSO. 
3.3.5 Quantification of lysosomal-mitochondrial interactions 
Mouse neonatal cardiomyocytes were treated with JQ1 or DMSO in the present of BSA 
or PA for 48h, labeled with LysoTrackerTM Deep Red (#12492, ThermoFisher Scientific) and 
MitoTracker® Green FM (#7514, Thermo Fisher Scientific) for 30 min at 37°C, and subjected to 
confocal microscopy (LSM800, Carl Zeiss Microscopy). Manders’ Correlation Coefficient was 
calculated using Image J software (National Institute of Health). 
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3.3.6 Immunofluorescence 
Mid-ventricles were fixed in phosphate buffered saline (PBS)/4% paraformaldehyde and 
embedded in paraffin. 4 µm-thick sections were subjected to xylene and alcohol for dehydration. 
Then, the slides were subjected to antigen retrieval using citrate buffer, permeabilized with 0.2% 
Triton X-100 and blocked with 5% normal goat serum (BioGenex, Fremont, CA). Or OCT 
embedded mid-ventricles were sliced to 6 µm-thick sections. The slides were rinsed with ddH2O 
and fixed in ice-cold acetone for 10 minutes. Then, the slides were permeabilized with 0.2% 
Triton X-100 and blocked with 5% normal goat serum. For primary antibodies, slides were 
incubated with rabbit anti-BRD4 (Abcam, 1:100 dilution) and mouse anti-cardiac troponin T 
(ThermoFisher Scientific, 1:1000 dilution) at 4°C overnight. Or slides were incubated with rabbit 
anti-LC3A/B (CST, 1:100 dilution) and mouse anti-ATP5A1 (proteintech, 1:200 dilution) at 4°C 
overnight. Alexa Fluor 555 goat anti-rabbit and 488 goat anti-mouse IgG (Invitrogen, 1:200 
dilution) were used as secondary antibodies, incubated at RT for 1 hour. Cell nuclei were stained 
with 4′, 6-diamidino-2-phenylindole (DAPI, Sigma). Samples were mounted with VectaMountTM 
AQ (#5501, Vector Laboratories) for fluorescence microscopy. 
3.3.7 Histological analysis 
Heart sections from the mid-ventricle were fixed in paraformaldehyde and embedded in 
paraffin; morphology was determined by H&E staining. Cardiomyocyte cross-sectional area was 
determined by staining with rhodamine-conjugated wheat germ agglutinin (Vector Laboratories 
RL-1022). Oil red O staining was performed to determined lipid accumulation. Fibrosis was 
visualized using a Picro-Sirius Red Stain Kit (#ab150681, Abcam). Terminal deoxynucleotidyl 
transferase dUTP nick-end label (TUNEL) staining was performed in wax sections of the left 
ventricle using TUNEL Enzyme and TUNEL Label Mix (Roche, 11767305001; 11767291910). 
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Cardiomyocyte cross-sectional area, lipid area, and fibrosis area were calculated using Image J 
software (National Institute of Health). 
3.3.8 Mouse heart mitochondrial isolation 
Adult mouse cardiac mitochondria was isolated using Mitochondrial Isolation Kits 
(#ab110168, abcam). All procedures followed manufacturer instructions. Briefly, freshly isolated 
left ventricle   heart tissue was washed with pre-chilled washing buffer, and minced in pre-
chilled isolation buffer. After spinning down at 1,000g, supernatant was transferred to a new 
tube. After a second spinning down at 12,000g, supernatant containing cytosol protein was 
collected. Then the pellet containing mitochondria was washed in isolation buffer supplemented 
with protease inhibitor cocktail (#7012, CST), and was collected for further use after spinning 
down at 12,000g. 
3.3.9 Measurement of mitochondrial OCR 
Mitochondrial OCR was determined using an XFe96 extracellular flux analyzer (Seahorse 
Biosciences) following the manufacturer’s instructions. All analyses were reported using the XF 
Cell Mito Stress Test Report Generator. Coupling Assay and Electron Transport Assay were 
performed in isolated mitochondria from adult mouse hearts according to the published protocol 
(23). 
3.3.10 Flow cytometry 
Mitochondrial ROS level was determined using MitoSOX™ Red (5 µM, M36008, 
ThermoFisher Scientific) as previously described (24). Briefly, mouse neonatal cardiomyocytes 
were incubated with the probe in analysis buffer (HBSS containing calcium and Magnesium), 
and cells were washed, trypsinized, and collected. Isolated mitochondria from adult mouse hearts 
were incubated with the probe and washed with analysis buffer as previously described (24). 
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Then, levels of mitochondrial ROS was measured using a Fortessa Flow Cytometer (BD 
Bioscience). A minimum of 10,000 events was collected for each sample. Quantitative analysis 
of the data was determined using FlowJo (v10) software. 
3.3.11 Transmission electron microscopy (TEM) 
Mouse heart samples were removed and fixed with 2.5% glutaraldehyde in 0.1 M 
cacodylate buffer (pH 7.4). Heart samples were then rinsed with 0.1 M cacodylate buffer (pH 
7.4) twice before post-fixation in 1% osmium tetroxide for 1 hour. After additional buffer rinses, 
heart samples were dehydrated through an ethanol series to 100% ethanol, infiltrated with a 
mixture of 100% propylene oxide and Eponate 12 resin (Ted Pella Inc., Redding, CA), followed 
by pure Eponate 12 resin overnight. Heart samples were embedded in beem capsules and placed 
in a 60°C oven for polymerization. Ultrathin sections were cut on a Leica UltraCut microtome at 
70-80 nm and placed on 200 mesh copper grids. Sections were then stained with 5% uranyl 
acetate for 15 minutes followed by 2% lead citrate for 15 minutes. Samples were imaged with a 
JEOL JEM-1400 transmission electron microscope (Tokyo, Japan) equipped with a Gatan 
US1000 CCD camera (Pleasanton, CA). Mitochondrial mass and lipid content were measured 
using Image J software (National Institute of Health). 
3.3.12 Western blotting 
Mouse tissues and cultured cardiomyocytes were homogenized using ice cold RIPA lysis 
buffer (#sc-24948, Santa Cruz Biotechnology). Protein contents were measured using the 
Bradford assay (#23225, Pierce Biotechnology). Detailed steps for western blotting were 
described previously (25). Primary antibodies information was shown in Table 3.1. 
90 
3.3.13 Quantitative real-time PCR 
Total RNA was extracted from cultured cardiomyocytes or mouse hearts using the 
RNeasy Mini Kit (#74106, QIAGEN) or TRIzol according to the manufacturer’s instructions. 
cDNA was synthesized using the iScriptTM cDNA Synthesis Kit (#170-8891, Bio-Rad 
Laboratories). All samples were run in triplicate and underwent initial denaturation at 95°C for 5 
min, followed by 40 rounds of amplification (95°C for 30 s, 60°C for 30 s) using iQTM SYBR® 
Green Supermix (#720001059, Bio-Rad Laboratories) and the CFX96TM Real-Time System 
(Bio-Rad Laboratories). All data were analyzed using the 2-ΔΔCT method as previously described 
(26). Primers information was shown in Table 3.2. 
3.3.14 ChIP-qPCR 
ChIP-qPCR was performed with the SimpleChIP® Enzymatic Chromatin IP Kit (# 9003, 
CST) following the manufacturer’s instructions. As previously described (27,28), mouse whole 
heart tissues from indicated treatment groups were homogenized and crosslinked with 1% 
formaldehyde and quenched with glycine. Then, nucleus samples were isolated and sonicated 
into 100-500 bp DNA fragments. Lysates in each chromatin solution then underwent 
immunoprecipitation with 5 µg of antibody, including anti-Brd4 (A301-985A100, BETHYL 
Laboratories, Inc.), anti-H3K27ac (8173S, CST), or anti-IgG (171870, Abcam) overnight at 4°C. 
The immunoprecipitated DNA samples were reversed crosslinked, purified, and amplified by 
quantitative PCR with specific primers designed to amplify the Pink1 promoter region (forward: 
5’-GGACCGCTACCGCTTCTTC-3’; reverse: 5’- CTTCCGCCTGCTTCTCCTC-3’). The 
enrichment of Pink1 gene DNA fragments was normalized against total genomic DNA input. 
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3.3.15 Statistical analysis 
All values are presented as mean ± SEM. Differences between experimental groups were 
determined by one-way or two-way ANOVA, followed by the Tukey post hoc test, as 
appropriate. Student t-tests were performed for single comparisons between groups. P < 0.05 was 
considered statistically significant. 
3.4 Results 
3.4.1 Increased BRD4 protein in HFD-induced Type 2 diabetic cardiomyopathy 
           We fed 2-month-old WT mice a ND or a HFD for 6 months to build Type 2 diabetic 
cardiomyopathy mouse model. To address the relationship between BET family proteins and 
diabetic cardiomyopathy, we first examined mRNA levels of Brd2, Brd3, and Brd4 in adult 
mouse hearts and mouse neonatal cardiomyocytes (Fig. 3.1A and B), and found that Brd4 
expression was most abundant in cardiomyocytes. Then we examined BRD2, BRD3, and BRD4 
protein expression in HFD-induced Type 2 diabetic mouse hearts. Compared with ND-fed mice, 
HFD-fed mice exhibited a significantly higher BRD4 level and normal BRD2 and BRD3 protein 
levels (Fig. 3.2A and B). However, HFD feeding did not increase Brd4 mRNA expression (Fig. 
3.1C). Finally, co-staining of BRD4 and the cardiomyocyte marker cardiac troponin T indicated 
that the increase in BRD4 expression mainly occurred in cardiomyocytes (Fig. 3.2C and D). 
Collectively, these results suggest a potential role for BRD4 in the development of diabetic 
cardiomyopathy.  
3.4.2 Suppression of PINK1/Parkin-mediated mitophagy in diabetic cardiomyopathy 
Next, we investigated the effects of HFD-feeding on the process of 
autophagy/mitophagy. We found that HFD feeding reduced PINK1 protein levels but had no 
effect on Parkin protein expression (Fig. 3.2E-G). Since cells possess several mitophagy 
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mechanisms, we further examined expression of mitophagy receptors and other proteins 
regulating mitophagy and found that HFD exposure did not alter expression of these proteins 
(Fig. 3.3A and B). Moreover, mitochondria can also be cleared through general autophagy 
pathway. Therefore, we investigated the effects of HFD-feeding on this process (Fig. 3.3C-F). 
We found the inhibition of autophagic flux in HFD-fed mice was likely due to blockage of 
lysosomal degradation of cargos, but not to autophagy initiation. Taken together, we reasoned 
that an accumulation of dysfunctional mitochondria may occurred in HFD-fed mouse heart.  
As shown in Figure 3.2H to J, protein levels of translocase of the inner membrane 23 
(TIM23) and voltage-dependent anion channel 1 (VDAC1) were markedly increased in the 
hearts of mice fed a HFD. Despite the increase in mitochondrial content, peroxisome 
proliferator-activated receptor γ coactivator-1α (PGC-1α) and mitochondrial transcription factor 
A (Tfam), two important molecules regulating mitochondrial biogenesis were decreased in hearts 
from mice fed a HFD (Fig. 3.3G and H). Since mitochondrial content homeostasis is dependent 
on the generation of new and the removal of damaged or unwanted mitochondria, our results 
suggested the increase in mitochondrial proteins in HFD-fed hearts is due to impairment of the 
ability of cardiomyocytes to remove damaged mitochondria. Then, we characterized 
mitochondrial function using Seahorse XF96 metabolic flux analyzer by directly isolating 
mitochondria from hearts of mice fed a ND or HFD. A significant reduction in State 3 and State 
3u oxygen consumption rate (OCR) were observed between HFD-fed and ND-fed mice (Fig. 
3.2K and L). OCR decreased dramatically in State 3u, but not State 40, suggesting a decreased 
mitochondrial respiratory control ratio (RCR) (State 3u/State 40) in HFD-fed mice hearts (Fig. 
3.2M). These data suggest that HFD feeding inhibits PINK1/Parkin-dependent mitophagy, 
leading to the accumulation of dysfunctional mitochondria in the hearts of diabetic mice. 
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3.4.3 Knockout of Pink1 worsens HFD-induced diabetic cardiomyopathy in mice 
Given that a HFD induces diabetic cardiomyopathy and concurrently suppresses 
PINK1/Parkin-mediated mitophagy, we examined the effect of Pink1 deficiency on the 
development of diabetic cardiomyopathy in vivo. After 4 months of HFD feeding, Pink1-/- mice 
developed diastolic dysfunction, indicated by reduced E/A-wave ratio (E-wave and A-wave 
represent LV early filling and filling from atrial contraction, respectively) (Fig. 3.4A and B), 
increased LV isovolumic relaxation time (IVRT) (Fig. 3.4C) and the ratio between early mitral 
inflow velocity wave (E) and mitral annular early diastolic velocity (E′) (E/E′) (Fig. 3.5A and 
B). Pink1-/- mice also developed profound systolic dysfunction, indicated by reduced ejection 
fraction (EF) and fractional shortening (FS) (Fig. 3.4D-F). However, WT mice exhibited no 
significant cardiac dysfunction between ND and HFD groups. After 6 months, WT mice 
developed profound diabetic cardiomyopathy. Deletion of Pink1 worsened diastolic and systolic 
dysfunction in both ND and HFD groups relative to those after 4-month HFD feeding (Fig. 
3.4A-F). In addition, interstitial fibrosis, lipid accumulation, and cell apoptosis were more 
apparent in Pink1-/- mice after 6-month HFD feeding (Fig. 3.4G-L). These data suggest the lack 
of Pink1 accelerates and exacerbates HFD-induced cardiomyopathy. 
3.4.4 Deletion of Pink1 aggravates the accumulation of dysfunctional mitochondria 
in the hearts of diabetic mice 
We next investigated the influence of Pink1 loss on mitophagy. We found that 
mitochondrial makers TIM23 and VDAC1 were markedly increased in HFD-fed WT mice; these 
increases were significantly aggravated in Pink1-/- mice (Fig. 3.6A-C). Transmission electron 
microscope (TEM) revealed that mitochondrial area and lipid droplet area were markedly 
increased in the hearts of HFD-fed WT mice and were further augmented in Pink1-/- mice (Fig. 
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3.6D-F). In addition, mitochondria isolated from the hearts of HFD-fed WT and ND-fed Pink1-/- 
mice exhibited reduced OCR in state 3 and state 3u, while HFD-fed Pink1-/- mice showed a 
dramatic OCR decrease in all states of respiration (Fig. 3.6G and H). Furthermore, HFD-fed WT 
mice exhibited a reduction in mitochondrial RCR, and this reduction was further decreased in 
Pink1-/- mice (Fig. 3.6I). Both HFD consumption and Pink1 deletion increased mitochondrial 
ROS production, and HFD-induced ROS overproduction was exacerbated by Pink1 deletion 
(Fig. 3.6J and K). These data suggest that lack of Pink1 exacerbates HFD-impaired mitophagy.  
3.4.5 Inhibition of BRD4 attenuates HFD-induced cardiomyopathy 
Since upregulation of BRD4 is associated with development of diabetic cardiomyopathy, 
we investigated if BRD4 inhibition prevents diabetic cardiomyopathy. We exposed 2-month-old 
WT mice to a ND or HFD for 7 months. During the last month, we randomized mice to receive 
JQ1 (10 mg/kg daily via intraperitoneal injection) or vehicle (DMSO). We found although 
administration of JQ1 resulted in minor reductions in EF, FS, and E/A ratio in ND-treated mice, 
JQ1 treatment completely prevented cardiac abnormalities in HFD-fed mice, restoring normal 
EF, FS, E/A ratio, IVRT, and E/E′ ratio (Fig. 3.7A-D, Fig. 3.8A-C). Concurrently, JQ1 treatment 
ameliorated HFD-induced cardiac hypertrophy (Fig. 3.7E), cardiomyocyte cross sectional area 
(Fig. 3.7F and G), interstitial fibrosis (Fig. 3.7I and J), lipid accumulation (Fig. 3.7K and L), 
and cardiomyocyte apoptosis (Fig. 3.7M and N). We further examined if JQ1 ameliorated 
cardiomyopathy in Type 2 diabetes by preventing metabolic abnormalities. We found that JQ1 
treatment prevented HFD-induced body weight increases, but did not affect mouse body weight 
in the ND group (Fig. 3.9A and B). Moreover, JQ1 treatment did not affect fasting blood 
glucose (Fig. 3.7H) or mouse whole-body energetics, as evidenced by a consistent respiratory 
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exchange ratio (RER) in the DMSO group (Fig. 3.9C and D). Together, these data suggest that 
BRD4 plays an important role in the pathogenesis of HFD-induced cardiomyopathy. 
3.4.6 BRD4 inhibition restores mitophagy and improves mitochondrial function in 
HFD-fed mice 
Next, we investigated if BRD4 inhibition could prevent diabetic cardiomyopathy by 
activating PINK1/Parkin-mediated mitophagy. We found that JQ1 treatment dramatically 
increased PINK1 expression in hearts from ND mice and attenuated HFD-induced reduction of 
PINK1 protein expression, but did not affect expression of BRD4 and Parkin. Concomitantly, 
JQ1 treatment attenuated the accumulation of mitochondria in HFD-fed mice, as evidenced by 
comparable levels of TIM23 and VDAC1 in JQ1-treated HFD mice and DMSO-treated ND mice 
(Fig. 3.10A-E). In addition, HFD feeding increased mitochondrial area, which was almost 
completely prevented by JQ1 treatment. JQ1 also significantly mitigated the increases in lipid 
droplet size and density in hearts from HFD-fed mice (Fig. 3.10F-H). To further investigate 
mitophagy in vivo, we co-stained mitochondria marker ATP synthase subunit alpha 
mitochondria-like protein (ATP5A1) with autophagosome marker LC3, using frozen section of 
mouse heart samples. We found HFD feeding decreased the colocalization of ATP5A1 and LC3, 
while JQ1 treatment elevated the colocalization, suggesting that mitophagy was rescued with 
JQ1 under HFD consumption (Fig. 3.11A and B). We next assessed the respiration capacity of 
adult mouse cardiac mitochondria, and found that JQ1 treatment significantly attenuated OCR 
reduction in state 3 and state 3u induced by HFD feeding (Fig. 3.10I and J). It also significantly 
prevented HFD inhibited RCR (Fig. 3.10K). Additionally, compared with ND feeding, HFD 
exposure markedly increased mitochondrial ROS production, and this increase was abolished by 
JQ1 treatment (Fig. 3.10L and M). Since the clearance of dysfunctional mitochondria can 
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through both mitophagy and general autophagy pathways (9), we also investigated the effect of 
JQ1 on general autophagy in mouse heart. As shown in Figure 3.12A to E, JQ1 administration 
increased overall autophagic flux under HFD condition, as evidenced by reducing the 
accumulation of LC3 II and p62 proteins.  Moreover, JQ1 treatment significantly increased 
LAMP1 protein expression under both ND and HFD condition. Taken together, these results 
suggest that JQ1 treatment mitigates HFD-induced cardiomyopathy by activating PINK1/Parkin-
mediated mitophagy and general autophagy pathways. 
We further tested if BRD4 inhibition with JQ1 increased mitophagy in mouse neonatal 
cardiomyocytes. Consistent with our findings in vivo, compared with BSA-treated control 
cardiomyocytes, PA treatment reduced lysosomal-mitochondrial interactions. In contrast, JQ1 
treatment significantly increased the colocalization of lysosome and mitochondria in both BSA-
and PA-treated cardiomyocytes (Fig. 3.13A and B). We then examined the effect of JQ1 on 
mitochondrial function and found that PA treatment significantly reduced basal and maximal 
respiration rate compared with BSA-treated controls. JQ1 treatment also significantly attenuated 
PA-enhanced maximal respiration rate and reduced proton leak, although it inhibited maximal 
respiration rate in BSA-treated cardiomyocytes (Fig. 3.13C and D). Moreover, PA-enhanced 
mitochondrial ROS production was completely abolished by JQ1 treatment (Fig. 3.13E and F). 
These results support the notion that the BRD4 inhibitor JQ1 prevents mitophagy suppression 
and improves mitochondrial function in HFD-fed conditions.   
3.4.7 Inhibition of BRD4 association with the Pink1 gene promoter activates 
PINK1/Parkin- mediated mitophagy 
BRD4 is a transcriptional regulator that recruits regulatory complexes to acetylated 
chromatin (29). We therefore examined whether HFD exposure and JQ1 treatment affect histone 
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acetylation in the heart. We found that HFD feeding increased histone protein acetylation and 
this increase was mitigated by JQ1 treatment (Fig. 3.14A and B). Interestingly, acetylated 
histone H3 lysine 27 (H3K27ac), a major site of BRD4 occupancy in the mouse heart (19), was 
increased in HFD-fed mice and this increase was attenuated by administration of JQ1 (Fig. 
3.14C and D). Thus, we reasoned that JQ1 regulates Pink1 gene expression by disrupting 
association of BRD4 with H3K27ac at the Pink1 promoter. To test this, we performed chromatin 
immunoprecipitation coupled with real-time PCR (ChIP-qPCR) using hearts from ND- or HFD-
fed and DMSO- or JQ1-treated mice. We observed an enrichment of both BRD4 (Fig. 3.14E and 
F) and H3K27ac (Fig. 3.14G and H) at the Pink1 promoter in HFD-fed mouse hearts and this 
enrichment was abolished by JQ1 administration.  
Next, we examined whether enrichment of BRD4 and H3K27ac at the Pink1 promoter 
affects Pink1 gene expression in cardiac tissues. We found that in the hearts of HFD-fed mice, 
Pink1 mRNA expression was significantly reduced. Administration of JQ1 restored normal 
levels of Pink1 mRNA in the hearts of HFD-fed mice (Fig. 3.14I). Since BRD4 knockdown 
induces the expression of a subset of autophagy and lysosome genes in KP-4 cells (30), we also 
studied if BET inhibition by JQ1 could regulate the expression of genes related to 
autophagy/mitophagy in cultured neonatal cardiomyocytes. PA induced significant decreases in 
Map1lc3b and Pink1 gene expression. JQ1 treatment markedly upregulated gene expressions of 
Atgs, including Map1lc3b, Sqstm1, Ulk1, Lamp1, Ctss, and Pink1 in both BSA- and PA-treated 
cells (Fig. 3.14J). These data suggest that BRD4 suppresses the expression of Pink1 gene, as 
well as genes regulating autophagy and lysosomal function. 
To further characterize the mechanisms by which JQ1 regulates mitophagy, we isolated 
mitochondrial fractions from ND- or HFD-fed and DMSO- or JQ1-treated mouse hearts to 
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analyze mitochondrial-associated Parkin translocation and downstream mitophagy events. 
Administration of JQ1 increased mitochondrial localization of PINK1, Parkin, and p62 in BSA-
treated cells, and it prevented PA-inhibited mitochondrial localization of PINK1, Parkin, and p62 
(Fig. 3.14K-N). Moreover, JQ1 treatment dramatically increased mitochondrial protein 
ubiquitination in both ND- and HFD-fed mouse hearts (Fig. 3.14O and P). Taken together, these 
data suggest that JQ1 inhibition stimulates PINK1/Parkin-mediated mitophagy signaling. 
3.4.8 Pink1 deletion abrogates JQ1-alleviated diabetic cardiomyopathy induced by 
HFD feeding 
To establish the essential role of PINK1/Parkin-mediated mitophagy in JQ1-alleviated 
diabetic cardiomyopathy, we fed 2-month-old Pink1-/- mice a ND or HFD for 7 months and 
treated mice with JQ1 or vehicle (DMSO) during the last month combined with HFD feeding. In 
contrast to the complete abrogation of HFD-induced diastolic and systolic dysfunctions under 
JQ1 treatment in WT mice, JQ1 treatment failed to restore normal cardiac functions in Pink1-/- 
mice, as evidenced by comparable EF, FS, and E/E′ values in JQ1- and DMSO-treated Pink1-/- 
mice fed a HFD (Fig. 3.15C and D, Fig. 3.16A-C); however, administration of JQ1 slightly 
alleviated HFD-reduced E/A ratio and IVRT values (Fig. 3.15A and B). Similarly, JQ1 
treatment did not prevent HFD-induced cardiac hypertrophy in Pink1-/- mice (Fig. 3.15E-G). 
Next, we assessed the effects of JQ1 on cardiac histopathological features. JQ1 administration 
significantly attenuated HFD-induced interstitial fibrosis (Fig. 3.15H and I), but could not 
alleviate HFD-induced lipid accumulation and cardiomyocyte apoptosis in Pink1-/- mice (Fig. 
3.15J-M). Taken together, these results support the notion that PINK1/Parkin-mediated 
mitophagy is an essential mediator for JQ1-induced improvement of diabetic cardiomyopathy. 
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3.5 Discussion 
In this study, we show that aberrant expression of BRD4 suppresses PINK1/Parkin-
mediated mitophagy, resulting in accumulation of dysfunctional mitochondria and development 
of diabetic cardiomyopathy. Inhibition of BRD4 using the selective bromodomain inhibitor JQ1 
restores PINK1/Parkin-mediated mitophagy, improves mitochondrial function, and consequently 
prevents impairment of cardiac structure and function in the hearts of diabetic mice. Importantly, 
Pink1 deletion suppresses mitophagy, exacerbates cardiomyopathy, and abrogates the therapeutic 
effect of JQ1 on diabetic cardiomyopathy.  
Mitophagy is a cellular process that removes dysfunctional or superfluous mitochondria 
(31), and shares its core molecular machinery with the autophagy pathway. Since damaged 
mitochondria lead to over-production of ROS and cell death (32,33), selective removal of 
dysfunctional mitochondria via mitophagy is an important mechanism of maintaining 
mitochondrial homeostasis and preserving cell viability. We previously showed that defective 
autophagy promotes heart failure, concurrent with enhanced protein aggregation and 
accumulation of damaged mitochondria in Type 1 diabetic mice (4,34). However, the functional 
role of autophagy/mitophagy in metabolic stress-induced cardiomyopathy remains controversial. 
Autophagy can either be suppressed (5-8) or activated (35,36) in the metabolically stressed heart. 
Notably, a recent study reported that 2 months of HFD feeding activated autophagic flux and 
mitophagy in mice. At the same time, these mice exhibited cardiac hypertrophy, diastolic 
dysfunction, and lipid accumulation (37).  
In the present study, we find that HFD-induced Type 2 diabetic mice exhibit marked 
increase in LC3-II and p62 protein levels and significant reduction in LAMP1 protein level. 
Notably, the BET inhibitor JQ1 promotes autophagic flux in HFD-fed mouse hearts and 
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increases expression of genes related to autophagy and lysosomal function in neonatal 
cardiomyocytes. However, we cannot determine whether the suppression of autophagy and 
lysosomal-related genes is also dependent on BRD4 binding to H3K27ac at their promoter 
regions. Concomitantly, we find that HFD exposure inhibits mitophagy, as indicated by increases 
in the mitochondrial proteins, TIM23 and VDAC1, with an even decreasing of mitochondrial 
biogenesis markers. Although the PINK1/Parkin pathway is considered the most important 
regulatory pathway in controlling mitophagy, the outer mitochondrial membrane proteins 
BNIP3L/Nix, BCL2-L-13, and FUNDC1 are also involved. In our study, suppression of 
mitophagy may be a result of PINK1 down-regulation, as HFD feeding only reduced PINK1 
protein and mRNA expression, but had no effect on other proteins regulating mitophagy. 
Furthermore, deletion of Pink1, which impairs PINK1/Parkin-mediated mitophagy, worsened 
HFD-induced diabetic cardiomyopathy. These observations strongly support the notion that 
suppression of PINK1/Parkin-mediated mitophagy may represent an essential mechanism for the 
pathogenesis of diabetic cardiomyopathy in Type 2 diabetes. However, multiple factors may 
collectively contribute to the development of diabetic cardiomyopathy in Type 2 diabetes, such 
as lipotoxicity, insulin resistance, and Ca+ imbalance, and possible molecular mechanisms linked 
to the development of cardiomyopathy include abnormalities in AMP-activated protein kinase, 
peroxisome proliferator-activated receptors, O-linked N-acetylglucosamine, protein kinase C, 
microRNA, and exosome pathways (38). Also, it is important to bear in mind that genetic Pink1 
gene deletion mice exhibit pathological cardiac phenotype at basal conditions due to disrupted 
mitophagy (39). Thus, HFD feeding worsened cardiomyopathy in Pink1-/- mice may be the 
combined effects of obesity in addition to inhibition of PINK1-mediated mitophagy. 
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Despite the fact that cardiac complications are a major cause of death in patients with 
diabetes, therapeutic strategies to effectively prevent or mitigate diabetic heart failure are still 
unavailable due to an incomplete understanding of the underlying mechanisms. Our work 
provides direct experimental evidence demonstrating that aberrant expression of cardiac BRD4 is 
a critical event in the development of diabetic cardiomyopathy, and inhibition of BRD4 with the 
selective bromodomain inhibitor JQ1 prevents HFD-induced impairment of cardiac structure and 
function. First, BRD4 is the most abundant BET family protein in cardiomyocytes; HFD-feeding 
significantly increased BRD4 protein levels, but did not alter those of BRD2 and BRD3. Second, 
upregulation of BRD4 is associated with the development of diabetic cardiomyopathy. Third, 
administration of JQ1 completely restored normal cardiac diastolic and systolic function in HFD-
fed mice. Finally, JQ1 treatment almost completely prevented HFD-induced cardiac 
hypertrophy, interstitial fibrosis, lipid accumulation, and cardiomyocyte apoptosis.  
BRD4 binds to acetylated histones and transcription factors through bromodomains and 
recruits transcriptional regulators such as positive transcription elongation factor b and the 
mediator complex (40). JQ1 is a selective bromodomain inhibitor that binds the bromodomain of 
BET proteins, resulting in transient displacement of bromodomain-containing proteins from 
acetylated chromatin (13). In this study, we observed an enrichment of both BRD4 and H3K27ac 
at the Pink1 gene promoter in hearts of HFD-fed mice, implying that BRD4 binds to H3K27ac at 
the Pink1 gene promoter region. However, enrichment of BRD4 and H3K27ac occupancy at 
Pink1 gene promotor was abolished by JQ1 treatment. Importantly, we found that mRNA 
expression of Pink1 and Atgs were significantly reduced in hearts of HFD-fed mice, in which 
association of BRD4 and H3K27ac at the Pink1 gene promoter was increased. JQ1 treatment 
abolished enrichment of BRD4 and H3K27ac at the Pink1 gene promoter and restored Pink1 
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mRNA to normal levels in hearts from HFD-fed mice, demonstrating that JQ1 upregulates Pink1 
mRNA expression by dissociating BRD4 from the Pink1 gene promoter. 
It is noteworthy that we used a dose of 10 mg/kg/day for the JQ1 treatment, which is 
four-times less than that used by other groups (16,17,19). We found that 50 mg/kg/day caused a 
dramatic body weight loss and HFD-fed mice died within one week (data not shown). The 
discrepancy may be due to differently aged mice. In our study, we treated mice at 8-9 months of 
age, while other groups treated mice at 10-12 weeks of age. In addition, diabetes is a metabolic 
syndrome that induces multi-organ dysfunction, including hepatic and renal dysfunction, which 
inhibits drug metabolism and excretion. Thus, it is of great importance to determine JQ1 dosage 
based on age, disease, disease stage, and disease severity. 
In summary, the present study establish that the selective bromodomain inhibitor JQ1 
prevents HFD-induced diabetic cardiomyopathy and provide mechanistic insights into the role of 
BRD4 in regulating PINK1/Parkin-mediated mitophagy. This mechanism provides a rationale 
for the development of BET bromodomain inhibitors as a new therapeutic approach for diabetic 
cardiomyopathy. 
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Figure 3.1 mRNA levels of BET family proteins in neonatal cardiomyocytes and adult mouse heart. 
A, Quantification of the mRNA levels of Brd2, Brd3, and Brd4 in adult mouse cardiac tissues, normalized 
to Brd2 (n = 4, ***P < 0.001 vs. Brd2). B, Quantification of the mRNA levels of Brd2, Brd3, and Brd4 in 
mouse neonatal cardiomyocytes, normalized to Brd2 (n = 4, ***P < 0.001 vs. Brd2). C, 2-month-old WT 
mice were fed ND or HFD for 6 months. mRNA level of Brd4 in mouse cardiac tissues from mice fed ND 
or HFD (n = 10/group). 
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Figure 3.2 Upregulation of BRD4 is associated with inhibition of PINK1-mediated mitophagy. 
2-month-old WT mice were fed ND or HFD for 6 months. A, Western blot analysis of BET family 
proteins, including BRD2, BRD3, and BRD4 in heart tissues from mice fed ND or HFD. B, 
Densitometric analysis of the indicated proteins (n = 8/group; ***P < 0.001 vs. ND). C, Representative 
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images of BRD4 immunofluorescent staining in hearts from ND- or HFD-fed mice. Nuclei were stained 
with DAPI and cardiomyocytes were stained with cardiac troponin T (cTNT). Scale bar, 50 µm. D, 
Percentage of cardiomyocytes with BRD4 staining (n = 8/group; ***P < 0.001 vs. ND). E, Western blot 
analysis of PINK1 and Parkin protein levels in heart tissues from mice fed ND or HFD. F, Densitometric 
analysis of PINK1 expression (n = 8/group; ***P < 0.001 vs. ND). G, Densitometric analysis of Parkin 
expression. H, Western blot analysis of mitochondrial marker proteins, including TIM23 and VDAC1 in 
mouse cardiac tissues. I, Densitometric analysis of TIM23 expression (n = 8/group; ***P < 0.001 vs. 
ND). J, Densitometric analysis of VDAC1 expression (n = 8/group; ***P < 0.001 vs. ND). K, 
Mitochondrial coupling of isolated mouse cardiac mitochondria was measured using a Seahorse XF96 
metabolic flux analyzer. L, Graph of respirations of different states (n = 3; *P < 0.05 vs. ND). M, 
Mitochondrial respiratory control ratio (RCR) (n = 4; *P < 0.05). 
 
109 
 
 
Figure 3.3 HFD feeding inhibits autophagic flux and mitochondrial biogenesis. 
2-month-old WT mice were fed ND or HFD for 6 months. A, Western blot analysis of mitophagy-related 
proteins, including FUN14 domain containing 1, BCL2 Interacting Protein 3 like, and BCL2-like protein 
13 in mouse cardiac tissues. B, Densitometric analysis of the indicated proteins. C, Western blot analysis 
of p62, LC3 I, and LC3 II protein levels of heart tissues from ND- or HFD-fed mice. D, Densitometric 
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analysis of the indicated proteins (n = 8/group; **P < 0.01, ***P < 0.001 vs. ND). E, Western blot 
analysis of ATG5, ATG7, Beclin1, and LAMP1 protein levels of heart tissues from mice fed ND or HFD. 
F, Densitometric analysis of the indicated proteins (n = 8/group; **P < 0.01 vs. ND). G, mRNA level of 
Ppargc1a in cardiac tissues of mice fed HFD or ND for 6 months (n = 6-8, *P < 0.05 vs. ND). H, mRNA 
level of Tfam in cardiac tissues of mice fed HFD or ND for 6 months (n = 8-10, ***P < 0.001 vs. ND).  
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Figure 3.4 Pink1 deletion accelerates and aggravates cardiomyopathy in HFD-fed mice. 
2-month-old WT and Pink1-/- mice were fed ND or HFD for 4 or 6 months. A, Representative Doppler 
flow measurements of mitral inflow. B, Ratios of the early (E) to late (A) ventricular filling velocities (n 
= 8-13/group; *P < 0.05). C, Left ventricular isovolumic relaxation time (IVRT) (n = 8-13/group; *P < 
0.05). D, Representative images of M-mode echocardiography. E, Ejection fraction (EF) (n = 8-13/group; 
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*P < 0.05). F, Fractional shortening (FS) (n = 8-13/group; *P < 0.05). 2-month-old WT and Pink1-/- mice 
were fed ND or HFD for 6 months. G, Representative Picro Sirius Red staining images of cardiac tissues. 
Scale bar, 50 µm. H, Quantitative analysis of Picro Sirius Red staining (n = 8/group; **P < 0.01, ***P < 
0.001). I, Representative Oil Red O staining images of cardiac tissues. Scale bar, 50 µm. J, Quantitative 
analysis of Oil Red O staining (n = 8/group; *P < 0.05, ***P < 0.001). K, Representative TUNEL 
staining images of cardiac tissues; nuclei were stained with DAPI. Scale bar, 50 µm. L, Quantitative 
analysis of TUNEL staining (n = 6/group, ***P < 0.001). 
 
 
 
Figure 3.5 E/E' of Pink1-/- mice fed a ND or HFD. 
2-month-old WT and Pink1-/- mice were fed ND or HFD for 4 months. A, Representative tissue Doppler 
images. B, Ratio between early mitral inflow velocity wave (E) and mitral annular early diastolic velocity 
(E′) wave (E/E′), n = 6-8/group; *P < 0.05, ***P < 0.001.  
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Figure 3.6 Pink1 deletion worsens mitochondrial dysfunction in HFD-fed mice. 
2-month-old WT and Pink1-/- mice were fed ND or HFD for 6 months. A, Western blot analysis of 
mitochondrial marker proteins, including TIM23 and VDAC1, in the hearts of WT or Pink1-/- mice fed 
with ND or HFD. B, Densitometric analysis of TIM23 (n = 6/group; *P < 0.05). C, Densitometric 
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analysis of VDAC1 (n = 6/group; *P < 0.05). D, Representative TEM images of cardiac mitochondria in 
WT or Pink1-/- mice fed ND or HFD for 6 months. Scale bar 1 µm. E, Quantification of mitochondrial 
area (n = 4/group; *P < 0.05, **P < 0.01). F, Quantification of lipid droplets (n = 4/group; *P < 0.05, **P 
< 0.01). G, Mitochondrial coupling of isolated mouse cardiac mitochondria was measured using a 
Seahorse XF96 metabolic flux analyzer. H, Graph of respirations of different states (n = 3; *P < 0.05). I, 
Mitochondrial respiratory control ratio (RCR) (n = 3; *P < 0.05, **P < 0.01). J, Flow cytometric analysis 
of mitochondrial ROS in isolated mitochondria from WT and Pink1-/- mice hearts by MitoSOX. K, Mean 
fluorescence intensity quantification (n = 4; *P < 0.05, **P < 0.01).   
 
115 
 
Figure 3.7 BRD4 inhibition with JQ1 potently alleviates cardiac dysfunction and cardiac remodeling in 
HFD-fed mice. 
2-month-old WT mice were fed ND or HFD for 7 months and treated with JQ1 during the last month of 
feeding. A, Ratios of the early (E) to late (A) ventricular filling velocities (n = 10/group; ***P < 0.001). 
B, Left ventricular isovolumic relaxation time (IVRT) (n = 10/group; **P < 0.01). C, Ejection fraction 
(EF) (n = 10/group; **P < 0.01, ***P < 0.001). D, Fractional shortening (FS) (n = 10/group; **P < 0.01, 
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***P < 0.001). E, Ratio of heart weight/tibia length (HW/TL) (n = 8/group; ***P < 0.001). F, 
Representative wheat germ agglutinin staining images of cardiac tissues. Scale bar, 50 µm. G, 
Quantitative analysis of cardiomyocyte cross-sectional area (n = 4/group; ***P < 0001). H, Fasting blood 
glucose (n = 8/group; ***P < 0.001). I, Representative Oil Red O staining images of cardiac tissues in 
indicated groups. Scale bar, 50 µm. J, Quantitative analysis of Oil Red O staining (n = 8/group; ***P < 
0.001). K, Representative Picro Sirius Red staining images of cardiac tissues in indicated groups. Scale 
bar, 50 µm. L, Quantitative analysis of Picro Sirius Red staining (n = 8/group; ***P < 0.001). M, 
Representative TUNEL staining images of cardiac tissues; nuclei were stained with DAPI. Scale bar, 50 
µm. N, Quantitative analysis of TUNEL staining (n = 6/group; ***P < 0.001 vs. DMSO HFD). 
 
 
 
 
 
Figure 3.8 E/E' of ND or HFD-fed WT mice treated with JQ1. 
2-month-old WT mice were fed ND or HFD for 7 months and treated with JQ1 during the last month of 
feeding. A, Representative Doppler flow measurements of mitral inflow. B, Representative tissue Doppler 
images. C, Ratio between early mitral inflow velocity wave (E) and mitral annular early diastolic velocity 
(E′) wave (E/E′), n = 7-9/group; ***P < 0.001.  
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Figure 3.9 Comprehensive metabolic monitoring for ND or HFD-fed WT mice treated with JQ1. 
2-month-old WT mice were fed ND or HFD for 7 months and treated with JQ1 for the last month of feeding. 
A, Body weight of ND-fed mice based on a daily record of the 30 days of JQ1 administration. B, Body 
weight of HFD-fed mice based on a daily record for the 30 days of JQ1 administration (n = 8/group; *P < 
0.05).  C, Mice were individually placed in metabolic cages (PhenoMaster) and allowed to acclimatize for 
3 days before RER (VCO2/VO2) readings were taken (n = 4 mice per group). D, Mean RER. 
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Figure 3.10 BRD4 inhibition with JQ1 promotes mitophagy and improves mitochondrial function in 
HFD-fed mice. 
2-month-old WT mice were fed ND or HFD for 7 months and treated with JQ1 during the last month of 
feeding. A, Western blot analysis of indicated proteins in heart tissues from DMSO- or JQ1-treated mice 
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fed a ND or HFD. B, Densitometric analysis of BRD4 (n = 6/group; *P < 0.05). C, Densitometric analysis 
of PINK1 (n = 6/group; *P < 0.05; **P < 0.01). D, Densitometric analysis of TIM23 (n = 6/group; *P < 
0.05; **P < 0.01). E, Densitometric analysis of VDAC1 (n = 6/group; *P < 0.05). F, Representative TEM 
images of cardiac mitochondria in DMSO- or JQ1-treated mice fed ND or HFD. Scale bar 1 µm. G, 
Quantification of the mitochondrial area ratio (n = 4/group; *P < 0.05). H, Quantification of lipid droplets 
(n = 4/group; **P < 0.01). I, Mitochondria coupling of isolated mouse cardiac mitochondria was 
measured using a Seahorse XF96 metabolic flux analyzer. J, Graph of respirations of different states (n = 
3; *P < 0.05). K, Mitochondrial respiratory control ratio (RCR) (n = 3; *P < 0.05; **P < 0.01). L, Flow 
cytometric analysis of mitochondrial ROS in isolated mitochondria from heart tissues of DMSO- or JQ1-
treated mice fed ND or HFD by MitoSOX. M, Mean fluorescence intensity quantification (n = 3; *P < 
0.05). 
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Figure 3.11 Colocalization of LC3 and ATP5A1 in the hearts of ND or HFD-fed WT mice treated with 
JQ1. 
2-month-old WT mice were fed ND or HFD for 7 months and treated with JQ1 during the last month of 
feeding. A, Representative images of ATP5A1 and LC3 immunofluorescent staining in hearts from ND- or 
HFD-fed mice treated with DMSO or JQ1. Nuclei were stained with DAPI. Scale bar, 20 µm. B, Enlarged 
images of selected area in penal A.  C, Colocalization analysis of ATP5A1 and LC3 (n = 5/group; *P < 
0.05, **P < 0.01). 
 
 
Figure 3.12 BRD4 inhibition with JQ1 promotes autophagy in HFD-fed mice. 
2-month-old WT mice were fed ND or HFD for 7 months and treated with JQ1 during the last month of 
feeding. A, Western blot analysis of indicated proteins in heart tissues from DMSO- or JQ1-treated mice 
fed a ND or HFD. B, Densitometric analysis of p62 (n = 6/group; *P < 0.05). C, Densitometric analysis of 
LC3 I. D, Densitometric analysis of LC3 II (n = 6/group; *P < 0.05). E, Densitometric analysis of LAMP1 
(n = 6/group; *P < 0.05).  
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Figure 3.13 BRD4 inhibition with JQ1 promotes mitophagy and improves mitochondrial function in 
cultured neonatal cardiomyocytes. 
Mouse neonatal cardiomyocytes were treated with DMSO or JQ1 in the presence of BSA or PA. A, 
Representative confocal images of mouse neonatal cardiomyocytes labeled with MitoTracker and 
LysoTracker. Scale bar, 20 µm. B, Colocalization analysis of MitoTracker and LysoTracker (n = 3; *P < 
0.05). C, Mitochondria OCR was measured using a Seahorse XF96 metabolic flux analyzer. D, Graph of 
basal respiration, proton leak, and maximal respiration (n = 3; *P < 0.05).  E, Flow cytometric analysis of 
mitochondrial ROS production in mouse neonatal cardiomyocytes by MitoSOX staining. F, Mean 
fluorescence intensity calculation (n = 3; **P < 0.01). 
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Figure 3.14 Molecular basis for JQ1 activation of PINK1/Parkin-mediated mitophagy. 
2-month-old WT mice were fed ND or HFD for 7 months and treated with JQ1 for the last month of 
feeding. A, Western blot analysis of total protein lysine acetylation (ac-Lysine) in heart tissues from 
DMSO- or JQ1-treated mice fed ND or HFD. B, Densitometric analysis of ac-Lysine levels (n = 4/group; 
*P < 0.05, ***P < 0.001). C, Western blot analysis of H3K27ac levels in heart tissues from ND- or HFD-
treated mice. D, Densitometric analysis of H3K27ac level (n = 6/group; *P < 0.05, ***P < 0.001). E, 
Results of ChIP-qPCR assay for BRD4 binding to the Pink1 gene promoter in mouse heart tissues (n = 
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4/group; *P < 0.05 [DMSO ND vs. DMSO HFD], #P < 0.05 [JQ1 HFD vs. DMSO HFD]). F, Image of 
BRD4 ChIP at the Pink1 gene promoter. G, Results of the ChIP-qPCR assay for H3K27ac binding to the 
Pink1 gene promoter in heart tissues (n = 4/group; *P < 0.05 [DMSO ND vs. DMSO HFD], #P < 0.05 
[JQ1 HFD vs. DMSO HFD]). H, Image of H3K27ac ChIP at the Pink1 gene promoter. I, Pink1 mRNA 
level in mouse heart tissues in indicated groups (n = 6/group; *P < 0.05, **P < 0.01). J, mRNA level of 
Atgs in mouse neonatal cardiomyocytes treated with DMSO or JQ1 in the presence of BSA or PA. (n = 3; 
*P < 0.05 vs. DMSO BSA, #P < 0.05 vs. DMSO PA). K, Mitochondrial fraction (Mito) was prepared 
using mouse heart samples. Western blot analysis of PINK1, Parkin, and p62 in the Mito fraction were 
shown. Lactate dehydrogenase (LDH) was used as a marker for the cytosol. Mitochondrial cytochrome c 
oxidase subunit IV (COXIV) was used as a marker for mitochondria. L, Densitometric analysis of PINK1 
expression (n = 3; *P < 0.05). M, Densitometric analysis of Parkin expression (n = 3; *P < 0.05). N, 
Densitometric analysis of p62 expression (n = 3; *P < 0.05). O, Western blot analysis of the total 
ubiquitinated protein level in the Mito fraction of mouse heart samples. P, Densitometric analysis of 
ubiquitinated protein expression in the Mito fraction (n = 3; *P < 0.05). 
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Figure 3.15 Pink1 deletion abrogates the therapeutic effect of JQ1 on cardiac dysfunction, lipid 
accumulation, and apoptosis in HFD-fed mice. 
2-month-old Pink1-/- mice were fed ND or HFD for 7 months and treated with JQ1 for the last month of 
feeding. A, Ratios of the early (E) to late (A) ventricular filling velocities (n = 8/group; *P < 0.05, ***P < 
0.001). B, Left ventricular isovolumic relaxation time (IVRT) (n = 8/group; *P < 0.05, **P < 0.01). C, 
Ejection fraction (EF) (n = 8/group; ***P < 0.001). D, Fractional shortening (FS) (n = 8/group; ***P < 
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0.001). E, Ratio of heart weight/tibia length (HW/TL) (n = 8/group; ***P < 0.001). F, Representative 
wheat germ agglutinin staining images in cardiac tissues. Scale bar, 50 µm. G, Quantitative analysis of 
cardiomyocyte cross-sectional area (n = 4/group; ***P < 0.001). H, Representative Oil Red O staining 
images of cardiac tissues. Scale bar, 50 µm. I, Quantitative analysis of Oil Red O staining (n = 5/group; 
**P < 0.01, ***P < 0.001). J, Representative Picro Sirius Red staining images of cardiac tissues. Scale 
bar, 50 µm. K, Quantitative analysis of Picro Sirius Red staining (n = 5/group; ***P < 0.001). L, 
Representative TUNEL staining images of cardiac tissues; nuclei were stained with DAPI. Scale bar, 50 
µm. M, Quantitative analysis of TUNEL staining (n = 5/group; *P < 0.05, ***P < 0.001). 
 
 
Figure 3.16 E/E' of ND or HFD-fed Pink1-/- mice treated with JQ1. 
2-month-old Pink1-/- mice were fed ND or HFD for 7 months and treated with JQ1 for the last month of 
feeding. A, Representative Doppler flow measurements of mitral inflow. B, Representative tissue Doppler 
images. C, Ratio between early mitral inflow velocity wave (E) and mitral annular early diastolic velocity 
(E′) wave (E/E′), n = 6-8/group; *P < 0.05, ***P < 0.001.  
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Table 3.1 Primary Antibody Information 
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4 Conclusions 
4.1 General discussion and significance 
            Atherosclerosis is a chronic inflammatory disease with plaque builds up inside the 
arteries. Atherosclerosis can affect any artery in the body, including arteries in the heart, brain, 
kidneys etc., and it can lead to serious problems including heart attack, stroke, or even death. The 
plaques contain lipids, inflammatory cells, VSMCs, and connective tissues. Plaque 
destabilization and rupture are key mechanisms that contribute to end-stage clinical events such 
as acute coronary syndromes and symptomatic carotid artery disease (1). Research studies 
indicate that proliferation and migration of VSMCs play an important role in maintaining plaque 
stability through the maintenance of a protective fibrous cap overlying the thrombotic lipid core of 
advanced lesions (2,3). Thus understanding key regulators of VSMCs proliferation and migration 
will facilitate future strategies to modulate the disease process. 
            In this dissertation, we demonstrated that KAT2A/GCN5 is the enzyme that mediates 
acetylation of TUBA and is degraded specifically through autophagy in VSMCs. However, 
KAT2A/GCN5 is firstly identified as a histone acetyl transferase to be involved in a broad range 
of cellular processes including gene transcription, differentiation, DNA repair, nucleosome 
assembly, and cell cycle regulation. In this work, we cannot exclude an indirect regulation of 
TUBA acetylation via other molecules. In addition, either increasing of acetylation or decreasing 
of deacetylation may increase the acetylation of TUBA under autophagy-deficient conditions. 
Although alternation of autophagy doesn’t change the expression of HDAC6 or SIRT2, which 
are known TUBA deacetylase (4), we cannot rule out the effects of other unknown TUBA 
deacetylase. While we showed that upregulation of microtubule acetylation leads to enhancement 
of microtubule stability, role of TUBA acetylation on microtubule stability has been 
controversial. Some studies indicated that TUBA acetylation had no effect on microtubule 
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polymerization, while some other studies reported that increased acetylation of TUBA by 
HDAC6 inhibition increases microtubule stability and inhibits cell motility. 
            Recent studies have revealed that activities of microtubule-based motors regulate the 
biogenesis and trafficking of autophagosomes (5). In this dissertation, we demonstrated that 
autophagy can, in turn, regulate microtubule dynamics and cell motility through modulating 
TUBA acetylation. While we showed that suppression of autophagy upregulates microtubule 
acetylation which results in enhancement of microtubule stability, the role of autophagy on 
microtubule stability seems to be different in different cell type. In cultured central nervous 
system neurons, activating autophagy stabilizes microtubules by degrading stathmin 2, a 
membrane-associated neuron-specific protein that destabilizes microtubule, which leads to 
promotion of axon growth after spinal cord injury (6). The role of autophagy in regulating 
VSMCs migration also remains debatable. Thus, further investigation of the role of autophagy in 
regulating VSMCs migration is an interesting topic of study. Typically, a mouse model with 
VSMC-specific deletion of autophagy-related genes, such as ULK1, may be useful for these 
investigations. 
            Diabetes mellitus (DM) which characterized by high blood glucose levels and 
dyslipidemia, is one of the most prevalent diseases worldwide. In parallel with the increase in 
diabetes mellitus, the prevalence of diabetic cardiomyopathy is increased to 12% in diabetic 
patients (7). Despite the rapid increase in the number of preclinical and clinical studies on 
diabetic cardiomyopathy in the past decades, the pathogenesis of this disease still remains 
unclear. As a consequence, no consensus has been reached regarding the effective approaches to 
treat diabetic cardiomyopathy or diabetes- related heart failure. Therefore, it is necessary and 
significant to reveal the mechanisms of diabetic cardiomyopathy. 
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In this dissertation, we found that Pink1 genetic deletion accelerates and exacerbates 
cardiac dysfunction in HFD-fed mice. However, Billia et al. showed that Pink1 global knockout 
mice exhibited pathological cardiac phenotype at basal conditions due to an impairment of 
mitochondrial function and redox homeostasis (8). Further, multiple factors may collectively 
contribute to the development of diabetic cardiomyopathy, such as hyperglycaemia, 
hyperlipidemia, increasing cardiac oxidative stress, inflammation, myocardial fibrosis, as well as 
mitochondrial dysfunction. Thus, in addition to inhibition of PINK1/Parkin-mediated mitophagy, 
HFD feeding worsened cardiomyopathy in Pink1 knockout mice may be the combined effects of 
accumulation of oxidative stress and obesity.  
            The first stage of diabetic cardiomyopathy is usually clinically asymptomatic, but is 
evidenced by cardiac diastolic dysfunction (reduction of early diastolic filling and an increase in 
atrial filling), increased ventricular stiffness, enlarged atrial, and elevated LV end-diastolic 
pressure. The second stage of diabetic cardiomyopathy is characterized by cardiac remodeling, 
LV hypertrophy, cardiac diastolic dysfunction, and the emergence of clinical indications of HF 
(9). In the second part of this dissertation, we generated diabetic cardiomyopathy mouse model 
by feeding two-month-old C57BL/6J mice with ND or HFD for six months. Profound cardiac 
diastolic dysfunction and systolic dysfunction were found, which indicate second state of 
diabetic cardiomyopathy. Our results showed that PINK1/Parkin-mediated mitophagy is reduced 
in the heart of second-stage diabetic cardiomyopathy, which is crucial for maintaining normal 
cardiac function in the settings of diabetes. However, mitophagy activity is precisely regulated 
by different pathways and may change during the pathological development of diabetic 
cardiomyopathy. Thus, further investigation of the role of mitophagy in the different stages of 
diabetic cardiomyopathy is an interesting topic of study. 
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            Type 2 diabetes is often associated with insulin resistance, which is a condition that all 
the cells in the body become less sensitive to the effects of insulin, so a higher level of insulin is 
required to maintain its physiological functions. Although our studies demonstrate that JQ1 
administration can rescue cardiac abnormities in diabetes complications through elevating 
general autophagy and PINK1/Parkin-mediated mitochondrial quality control, an important 
question still need to be answered is whether the beneficial effect of JQ1 on cardiac function is 
due to its influence on the whole body insulin resistance condition. It is noteworthy that we used 
a dose of 10 mg/kg/day for the JQ1 treatment, which is four-times less than that used by other 
groups. We found that 50 mg/kg/day caused a dramatic body weight loss and death of HFD-fed 
mice within one week. The discrepancy may be due to difference of mice aged and diabetic 
condition, which inhibits drug metabolism and excretion by inducing multi-organ dysfunction, 
including hepatic and renal dysfunction. Thus, it is of great importance to optimize the dosage of 
JQ1 based on age, disease, disease stage, and disease severity. In this dissertation, we 
demonstrated that the specific BET bromodomain inhibitor JQ1 injection restores HFD-induced 
diabetic cardiomyopathy in WT mice. However, the mammalian BET family comprises BRD2, 
BRD3, BRD4, and testis-specific BRDT. Studying the effect of the specific protein on the 
pathogenesis of the disease has proven to be a challenging problem. Further investigation using 
BET proteins cardiac specific knockout mice are helpful means to study the molecular 
mechanism underlying therapeutic effect of JQ1 on HFD-induced diabetic cardiomyopathy. 
4.2 Conclusions and perspectives 
            This dissertation systemically studied the regulation of cardiovascular homeostasis by 
autophagy. Firstly, we discovered a novel autophagy-dependent degradation pathway for an 
acetyltransferase that regulates VSMCs migration at physiology condition. Secondly, we 
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expanded our work to disease condition, which includes novel insights into the underlying 
molecular mechanisms of diabetic cardiomyopathy. Finally, we identified JQ1, a BET inhibitor, 
as a therapeutic intervention in the diabetic cardiomyopathy. 
            The complete pathophysiology of cardiovascular diseases, which are the leading cause of 
death globally, are still being elucidated. Autophagy and mitophagy play an important role in the 
modulation of cellular homeostasis. It is likely that dysfunctional autophagy contributes to the 
morbidity and mortality associated with cardiovascular diseases. Further studies are certainly 
required to clarify many aspects of molecular mechanisms underlying autophagy regulation of 
cardiovascular homeostasis, which are essential for identifying effective preventive strategies 
and treatments. 
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